

From the Department of Laboratory Medicine  
Karolinska Institutet, Stockholm, Sweden

# MITOCHONDRIAL DYSFUNCTION AND TREATMENT STRATEGIES

Shuba Krishnan



**Karolinska  
Institutet**

Stockholm 2016

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by Printed by E-print AB 2016

© Shuba Krishnan, 2016

ISBN 978-91-7676-476-3

# Mitochondrial Dysfunction and Treatment Strategies

## THESIS FOR DOCTORAL DEGREE (Ph.D.)

By

**Shuba Krishnan**

*Principal Supervisor:*

Professor Anna Karlsson  
Karolinska Institutet  
Department of Laboratory Medicine  
Division of Clinical Microbiology

*Co-supervisor(s):*

Dr. Xiaoshan Zhou  
Karolinska Institutet  
Department of Laboratory Medicine  
Division of Clinical Microbiology

Dr. Sophie Curbo  
Karolinska Institutet  
Department of Laboratory Medicine  
Division of Clinical Microbiology

*Opponent:*

Professor Staffan Eriksson  
Swedish University of Agricultural Sciences  
Department of Anatomy, Physiology and  
Biochemistry  
Division of Veterinary Medical Biochemistry

*Examination Board:*

Docent Maria Eriksson  
Karolinska Institutet  
Department of Biosciences and Nutrition

Docent Liya Wang  
Swedish University of Agricultural Sciences  
Department of Anatomy, Physiology and  
Biochemistry

Docent Linda Björkhem Bergman  
Karolinska Institutet  
Department of Laboratory Medicine  
Division of Clinical Microbiology



*It's the circle of life  
It moves us all  
Through despair and hope  
Through faith and love  
Till we find our place  
In the path unwinding  
In the circle of life*

♥ *The Lion King*

**வினைத்திட்டம் என்ப தோருவன் மனத்திட்டம்  
மற்றைய எல்லாம் பிற**

*(Firmness in action is simply one's firmness of mind)*

- Thiruvalluvar

Dedicated to **அப்பா & அம்மா** (Dad and Mom)



## ABSTRACT

The mitochondria are essential for cellular energy production and are involved in many processes in the cells. The mitochondria contain their own DNA (mtDNA) that is vital for oxidative phosphorylation since it encodes enzymes of the respiratory chain. Mutations in the mtDNA and alterations in the mtDNA copy number are attributed to various human disorders including cancer. Mitochondrial DNA depletion syndromes (MDS) are a heterogeneous group of disorders characterized by severe depletion of the mtDNA. MDS predominantly manifests in high energy demanding tissues such as the skeletal muscle, brain and liver. Mutations in the genes that are responsible for providing precursors for the mtDNA synthesis such as thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) are known to cause MDS.

In an attempt to rescue the mtDNA depletion caused by thymidine kinase 2 (*Tk2*) deficiency in mice, the deoxyribonucleoside kinase from *Drosophila melanogaster* (*Dm-dNK*) was expressed in the *Tk2* deficient mice (*Dm-dNK<sup>+/-</sup>Tk2<sup>-/-</sup>*). The *Dm-dNK<sup>+/-</sup>* expression was able to rescue the *Tk2<sup>-/-</sup>* mice and prolong their life span from 3 weeks to up to 20 months. The *Dm-dNK* expression driven by the CMV promoter was observed in all tissues with highest expression in skeletal muscle and lower expression in heart, liver and adipose tissues. *Dm-dNK<sup>+/-</sup>Tk2<sup>-/-</sup>* mice maintained normal mtDNA levels in the skeletal muscle and liver throughout the observation time of 20 months. The *Dm-dNK* expression resulted in highly elevated dNTP pools with dTTP pools being >100 times higher than in the wild type mice. However, the large increase in the dTTP pool did not cause mutations in the nuclear or the mitochondrial DNA. A significant reduction in total body fat (both subcutaneous and visceral fat) was observed only in the *Dm-dNK<sup>+/-</sup>Tk2<sup>-/-</sup>* mice compared to wild type mice, which indicates an altered fat metabolism in these mice mediated through residual *Tk2* deficiency.

To elucidate effective treatment strategies for TK2 deficiency, a novel mouse model with liver specific expression of *Dm-dNK* driven by the albumin promoter was generated. Two founder mice with high *Dm-dNK* expression and activity in the liver was selected for further characterization. These mice will be used to study whether *Dm-dNK* expression in a single tissue would be able to rescue the severe phenotype caused by *Tk2* deficiency in mice.

The mitochondrial dicarboxylate carrier, SLC25A10, is involved in the transport of dicarboxylates such as malate and succinate across the mitochondrial inner membrane. To understand the role of the SLC25A10 carrier in regulating cancer cell growth, metabolism and transformation, a knockdown of SLC25A10 in a lung adenocarcinoma cell line (A549) was established and characterized. The growth properties of SLC25A10 knockdown cells changed to a less malignant phenotype, with increased dependency on glutamine and altered NADPH production. An increase in expression of glutamate dehydrogenase and decrease in expression of lactate dehydrogenase indicated a metabolic shift from glycolysis to oxidative phosphorylation in the SLC25A10 knockdown cells. The study demonstrates the importance of SLC25A10 in and regulation of redox homeostasis.

## LIST OF SCIENTIFIC PAPERS

- I. **Shuba Krishnan\***, Xiaoshan Zhou\*, João A. Parades, Raoul, V. Kuiper, Sophie Curbo, Anna Karlsson.  
Transgene Expression of *Drosophila melanogaster* Nucleoside Kinase Reverses Thymidine Kinase 2 Deficiency.  
*J Biol Chem.* **2013** Feb 15; 288(7):5072-5079.  
\*These authors contributed equally to this study
  
- II. **Shuba Krishnan**, João A. Parades, Xiaoshan Zhou, Raoul, V. Kuiper, Kjell Hultenby, Sophie Curbo, Anna Karlsson.  
Long Term Expression of *Drosophila melanogaster* Nucleoside Kinase in Thymidine Kinase 2-deficient Mice with no Lethal Effects Caused by Nucleotide Pool Imbalance.  
*J Biol Chem.* **2014** Nov 21; 289(47):32835-32844.
  
- III. **Shuba Krishnan**, Xiaoshan Zhou, Sophie Curbo, Anna Karlsson.  
Construction of a mouse strain with liver specific expression of *Drosophila melanogaster* nucleoside kinase.  
*Manuscript*
  
- IV. Xiaoshan Zhou, João A. Paredes, **Shuba Krishnan**, Sophie Curbo, Anna Karlsson.  
The mitochondrial carrier SLC25A10 regulates cancer cell growth.  
*Oncotarget.* **2015** Apr 20; 6(11):9271-9283.



# TABLE OF CONTENTS

<b>1</b>	<b>Introduction .....</b>	<b>1</b>
<b>2</b>	<b>The DNA Molecule.....</b>	<b>1</b>
	2.1 <i>The human genome .....</i>	2
	2.2 <i>The synthesis of deoxyribonucleotides .....</i>	3
	2.3 <i>Genomic stability and dNTP balance.....</i>	5
<b>3</b>	<b>Models to study genetic diseases.....</b>	<b>6</b>
	3.1 <i>The Drosophila melanogaster model organism.....</i>	6
	3.2 <i>The mouse (Mus musculus) model organism .....</i>	7
<b>4</b>	<b>Mitochondria.....</b>	<b>7</b>
	4.1 <i>Mitochondrial DNA depletion syndromes.....</i>	8
	4.2 <i>Animal models for MDS.....</i>	12
	4.3 <i>Cancer cell metabolism.....</i>	14
<b>5</b>	<b>Treatment strategies for mitochondrial dysfunction .....</b>	<b>17</b>
<b>6</b>	<b>Aim of the present work .....</b>	<b>19</b>
<b>7</b>	<b>Reflection on the methodology.....</b>	<b>20</b>
	7.1 <i>Transgene Constructs .....</i>	20
	7.2 <i>Mice .....</i>	21
	7.3 <i>Mitochondrial DNA copy number .....</i>	21
	7.4 <i>Measurement of dNTP pools.....</i>	21
	7.5 <i>Mutation analysis .....</i>	22
<b>8</b>	<b>Brief summary of results .....</b>	<b>23</b>
	8.1 <i>Paper I.....</i>	23
	8.2 <i>Paper II.....</i>	23
	8.3 <i>Paper III (manuscript) .....</i>	24
	8.4 <i>Paper IV.....</i>	24
<b>9</b>	<b>Concluding remarks.....</b>	<b>25</b>
<b>10</b>	<b>Acknowledgements.....</b>	<b>26</b>
<b>11</b>	<b>References.....</b>	<b>30</b>

## LIST OF ABBREVIATIONS

adPEO	autosomal dominant PEO
bp	base pairs
CMV	cytomegalovirus
COX	cytochrome C oxidase
dCK	deoxycytidine kinase
dGK	deoxyguanosine kinase
<i>Dm</i> -dNK	<i>Drosophila melanogaster</i> nucleoside kinase
dNK	deoxyribonucleoside kinases
FADH <sub>2</sub>	reduced form of flavin adenine dinucleotide
MDS	mitochondrial DNA depletion syndromes
MNGIE	mitochondrial neurogastrointestinal encephalomyopathy
MRC	mitochondrial respiratory chain complex
NADH	reduced form of nicotinamide adenine dinucleotide
NADPH	reduced form of nicotinamide adenine dinucleotide phosphate
NDPK	nucleotide diphosphate kinase
NMPK	nucleotide monophosphate kinase
OMIM	Online Mendelian Inheritance in Man
OxPhos	oxidative phosphorylation
P53R2	P53 inducible R2 subunit of ribonucleotide reductase
PEO	progressive external ophthalmoplegia
PNC	pyrimidine nucleotide carriers
Pol	polymerase
PRPP	phosphoribosyl pyrophosphate
RNR	ribonucleotide reductase
ROS	reactive oxygen species
SLC25	solute carrier family 25
TCA cycle	tricarboxylic acid cycle
TK1	thymidine kinase 1
TK2	thymidine kinase 2

### Nucleosides, nucleotides and nucleic acids

A, G, T, C	adenine, guanine, thymine, cytosine
dN	deoxyribonucleoside
Ado, dAdo	adenosine, deoxyadenosine
Cyt, dCyt	cytidine, deoxycytidine
dThd	deoxythymidine
Guo, dGuo	guanosine, deoxyguanosine
Urd, dUrd	uridine, deoxyuridine
dA, dAMP, dADP, dATP	deoxyadenosine, mono-, di- and tri- phosphate
dC, dCMP, dCDP, dCTP	deoxycytidine, mono-, di- and tri- phosphate
dG, dGMP, dGDP, dGTP	deoxyguanosine, mono-, di- and tri- phosphate
dT, dTMP, dTDP, dTTP	deoxythymidine, mono-, di- and tri- phosphate
dU, dUMP, dUDP, dUTP	deoxyuridine, mono-, di- and tri- phosphate

ATP	adenosine triphosphate
NMP, NDP, NTP	any ribonucleoside mono-, di- and tri- phosphate
DNA	deoxyribonucleic acid
RNA	ribonucleic acid
nDNA	nuclear DNA
mtDNA	mitochondrial DNA

### **Genes**

<i>C10ORF2</i>	twinkle helicase
<i>DCK</i>	deoxycytidine kinase
<i>DGUOK</i>	deoxyguanosine kinase
<i>MPV17</i>	mitochondrial inner membrane protein 17
<i>mt-Cytb</i>	mitochondrial cytochrome b
<i>NCR</i>	non-coding region
<i>POLG</i>	polymerase gamma
<i>RRM1, RRM2</i>	ribonucleotide reductase subunit M1 and M2
<i>RRM2B</i>	p53 inducible ribonucleotide reductase subunit 2
<i>SUCLG1, SUCLA2</i>	succinate coenzyme A ligase $\alpha$ - and $\beta$ - subunits
<i>TK1</i>	thymidine kinase 1
<i>TK2</i>	thymidine kinase 2
<i>TYMP</i>	thymidine phosphorylase
<i>UPP</i>	uridine phosphorylase



# **1 INTRODUCTION**

Abnormalities in the genome, with subsequent alterations of gene functions, are common causes of diseases. Genetic diseases may be hereditary or caused by new mutations or alterations in the DNA. Sometimes a single gene is mutated but more often genetic disorders are complex with involvement of several genes and effects of lifestyle and environmental factors. Mitochondrial dysfunction constitutes a large group of genetic inherited metabolic disorders which are due to deficient energy production by the mitochondrial respiratory chain complex. Genetic defects in both the nuclear and the mitochondrial DNA or defects in the inter-genomic signaling can result in mitochondrial dysfunction. Mitochondrial dysfunction contributes to a wide variety of diseases including neonatal fatality, adult onset neurodegeneration and cancer (1). Mitochondrial DNA depletion syndrome is characterized by reduced levels of mitochondrial DNA that largely affects infants and children and leads to early death (2). Deficiencies in enzymes that participate in the DNA precursor synthesis are among the genetic disorders that cause mitochondrial DNA depletion syndromes. Furthermore mitochondria are known to play an important role in the regulation of cell proliferation and cell death and are involved in the altered metabolism of cancer cells. To elucidate metabolic pathways that are important in cancer cell proliferation is a way to identify novel targets for cancer therapy.

# **2 THE DNA MOLECULE**

Deoxyribonucleic acids (DNA) are the molecules that carry the genetic information of life. DNA are long polymers made of repeating units called deoxyribonucleotides that are arranged in specific triplets that make up the genetic code. Deoxyribonucleotides are composed of a nitrogenous purine or pyrimidine nucleobase, bound to a 5-carbon deoxyribose sugar and one, two or three phosphate groups. The nucleobases are classified into two groups; the purines adenine (A) and guanine (G), and the pyrimidines cytosine (C), and thymine (T). The DNA molecule is a double stranded helical molecule, containing millions of bases linked to each other by phosphodiester bonds and between each other by hydrogen bonds (3). Bases A and T and bases C and G form double or triple hydrogen bonds with each other respectively (figure 1).




Figure 1: Deoxyribonucleotide structure

## 2.1 THE HUMAN GENOME

The human genome includes DNA present in two organelles in the cell; the nuclear DNA (nDNA) and the mitochondrial DNA (mtDNA). The majority of the genetic information in eukaryotic cells is encoded in the nDNA, while the mtDNA constitute about 2-3% of the total genome and encodes proteins essential for the synthesis of ATP.

### 2.1.1 The nuclear DNA

The nDNA consists of linear, double stranded molecules that form double helical structures and are tightly packed within the nucleus of a cell. Humans have a diploid genome containing approximately 3 million base pairs (bp) packed in 23 pairs of chromosomes. Chromosomes can be classified as autosomes and allosomes (sex chromosomes). Chromosomal pairs 1-22 in the human genome are autosomal while allosomes are the X and the Y chromosomes (XX for female and XY for male).

DNA replication is the process where novel DNA molecules are synthesized from deoxyribonucleoside triphosphates (dNTPs), using one strand as template. The two strands of the DNA double helix unwind with the help of helicases and form a replication fork (two single stranded templates) that each serve as templates for the synthesis of daughter strands. Several DNA polymerases exist that assist the DNA synthesis by addition of correct dNTPs to synthesize a complementary strand.

The nDNA synthesis is a tightly regulated process and occurs in specific phases of the cell cycle. In the  $G_1$  phase the replication process is initiated and all the proteins and factors required for synthesis are assembled. The majority of nDNA synthesis in eukaryotic cells occurs during the S phase of the cell cycle. Following the S phase, the  $G_2$  phase checks for damage or errors during DNA synthesis and prepares the cell for mitosis to form 2 daughter

cells. The daughter cells enter the G<sub>1</sub> phase again and the process repeats itself. Cells can also enter a non-dividing state, which is either not reversible (senescence or apoptosis), or a non-proliferative phase (G<sub>0</sub> phase, resting phase or quiescence). There are several check points in the cell cycle that ensures that DNA synthesis occurs without errors (4).

### 2.1.2 The mitochondrial DNA

Mitochondria contain their own DNA, the mtDNA, which contains genes encoding respiratory chain complexes. Compared to the linear nDNA, the mtDNA are circular double stranded molecules (16.5 kbp), that contain only 37 genes. 100-10,000 copies of mtDNA are present in each cell depending on the energy requirement of the specific cell. The mtDNA replication is independent of the cell cycle and the nDNA replication. Unlike nDNA that divides during the S phase of the cell cycle, mtDNA replication occurs asynchronously throughout the cell cycle and also occurs in post-mitotic resting cells such as brain and muscle cells. The mtDNA replication requires a constant supply of dNTPs and is regulated by several nuclear encoded proteins such as DNA polymerase  $\gamma$  (POLG), twinkle helicase and mitochondrial single-stranded DNA binding proteins (5-8).

## 2.2 THE SYNTHESIS OF DEOXYRIBONUCLEOTIDES

Depending on the cell cycle phase, cells can be classified as dividing cells or resting cells. In addition to the different enzymes and co factors, an adequate supply of dNTPs (dATP, dCTP, dTTP and dGTP), are required for DNA synthesis and repair in both dividing and resting cells. There are two tightly regulated pathways for nucleotide biosynthesis; the *de novo* pathway and the salvage pathway (figure 2).




Figure 2: Deoxyribonucleotide synthesis in the cytosol and mitochondria

The *de novo* pathway assembles ribonucleotides from sugars and amino acids. Ribose-5-phosphate, a product of glucose breakdown via the pentose phosphate pathway, reacts with ATP to generate the activated form, phosphoribosyl pyrophosphate (PRPP). PRPP, along with amino acids and carbon dioxide forms inositol monophosphate, which is subsequently converted to adenosine and guanosine monophosphates. Pyrimidines are assembled using bicarbonates, ATP, glycine and coenzyme Q, and are finally attached to PRPP to form uridine monophosphate. Nucleoside monophosphates are reversibly phosphorylated to nucleoside diphosphates (NDPs) catalyzed by nucleotide monophosphate kinases (NMPK). In humans, there are different NMPKs for the different nucleosides; thymidylate kinase, uridylate-cytidylate kinase, several isoforms of adenylate and guanylate kinases (9,10).

The enzyme ribonucleotide reductase (RNR) catalyzes the conversion of NDPs to deoxyribonucleoside diphosphates (dNDPs) by reduction of nucleotides in the 2-hydroxyl group of the sugar moiety (11). Since DNA requires thymidine deoxyribonucleotides, dUMP is converted to dTMP through reductive methylation catalyzed by the enzyme thymidylate synthase. The dNDPs are subsequently phosphorylated into respective dNTPs catalyzed by the enzyme nucleoside diphosphate kinase (NDPK) (12). In humans there are several NDPK isozymes, differentially expressed in tissues, possessing several different yet specific functions in the cell (13,14).

The salvage pathway employs enzymes known as deoxyribonucleoside kinase (dNK) to catalyze the phosphorylation of deoxyribonucleosides that are either recycled from degraded DNA or obtained from nutrients. Mammals have four dNKs with specific but overlapping substrate specificities and all encoded by the nDNA (15,16) (Table 1). Two of the enzymes are cytosolic; thymidine kinase 1 (TK1), and deoxycytidine kinase (dCK), and two of the enzymes are located in the mitochondria; thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK). The phosphorylation of deoxyribonucleosides to dNMPs by dNKs is the first and rate-limiting step in the salvage pathway. The dNMPs are subsequently phosphorylated to di- and tri- phosphates by NMPK and NDPK respectively.

*Table 1: The four mammalian dNKs, their substrates and expression*

<b>Enzyme</b>	<b>Human gene</b>	<b>Subcellular localization</b>	<b>Substrates</b>	<b>Expression pattern</b>
TK1	<i>TK1</i>	cytosol	dThd, dUrd	S phase
TK2	<i>TK2</i>	mitochondria	dThd, dUrd, dCyt	Constituent
dCK	<i>DCK</i>	cytosol	dCyt, dGuo, dAdo	Constituent
dGK	<i>DGUOK</i>	mitochondria	dAdo, dGuo	Constituent

### 2.2.1 The synthesis of dNTPs in dividing cells

The major source of dNTPs for DNA synthesis in dividing cells are from the *de novo* pathway, where the RNR catalyzes the rate limiting step in DNA synthesis. RNRs are tetrameric proteins containing two non-identical subunits: a large regulatory subunit R1 and a



small catalytic subunit R2 (17-19). In dividing cells, enzyme levels and activity of the R1 subunit is constant throughout the cell cycle, while the R2 subunit is cell cycle (S phase) regulated (18,20,21). Another source of dNTPs in dividing cells is via the salvage pathway mediated by the dNKs. TK1 activity is cell cycle regulated, and is highly S-phase specific, while dCK, dGK and TK2 are constitutively expressed throughout the cell cycle (15,22). Supply of dNTPs for mtDNA synthesis in dividing cells are likely both from the *de novo* and salvage pathways.

### **2.2.2 The synthesis of dNTPs in resting cells**

Resting cells do not undergo cell division and therefore do not have nDNA synthesis. However, mtDNA is constantly replicating and requires dNTP supply also in resting cells. The two constitutively expressed dNKs that are located in the mitochondria, TK2 and dGK, supply the required dNTPs for mtDNA synthesis in resting cells (23-27). Furthermore, the nDNA is constantly subjected to DNA damage and also requires an adequate supply of dNTPs for DNA repair. Expression of the R2 subunit of RNR and TK1 are undetectable in resting cells (28-30). The cytosolic/nuclear dCK phosphorylates dAdo, dGuo and dCyt deoxynucleosides (31).

The *P53* is a tumor suppressor gene and has been shown to be inactivated in a wide range of cancers (32,33). A p53 inducible ribonucleotide reductase subunit (p53R2) is similar to the R2 subunit of RNR (34). The p53R2 is expressed throughout the cell cycle and shown to supply dNTPs to both mtDNA and nDNA in resting cells in response to various radiation and genotoxic stress causing DNA damage (35-38).

### **2.3 GENOMIC STABILITY AND dNTP BALANCE**

DNA synthesis requires an adequate and balanced supply of dNTPs in order to function normally (19,39,40). Abnormal dNTP pools are known to cause mutagenic phenotypes, and correctly regulated dNTP pools are therefore a critical factor in maintaining genomic stability (41,42). The mtDNA corresponds to a small percentage of the total DNA and only small amounts of precursors are needed in comparison to the much larger nuclear DNA. Due to these differences mtDNA maintenance needs small but continuously present dNTP levels whereas nuclear DNA replication demands higher levels but restricted to the S phase of the cell cycle (43).

To keep the dNTP pools balanced their synthesis is regulated either by allosteric regulation of RNR or feedback inhibition of dNKs (19,44), or by substrate cycles involving catabolic enzymes that degrade deoxynucleotides (19). Several enzymes such as nucleotidases, purine nucleoside phosphorylases, adenosine deaminase, thymidine phosphorylase, sterile  $\alpha$  motif HD-domain containing protein 1 and uridine phosphorylase are catabolic enzymes that breakdown deoxyribonucleotides and deoxyribonucleosides to smaller bases and sugars that can either be excreted through the urine or recycled in the cell for different cellular processes. Mutations or deletions in any of the enzymes involved in the

regulation of the dNTP pool balance affects the fidelity of DNA synthesis and contribute to a variety of human disorders (40,45).

The mitochondrial dNTP pool is separated from the cytosolic pool by the mitochondrial inner membrane, which is impermeable to charged molecules (46,47). However, several studies show a communication between the cytosolic and the mitochondrial dNTP pools with transporters present in the inner mitochondrial membrane (48-50). The equilibrative nucleoside transporters are located in both the plasma membrane as well as the mitochondrial inner membrane where they facilitate deoxyribonucleoside transport into the mitochondria (51,52). Mitochondrial pyrimidine nucleotide carriers (PNC1, PNC2) transport deoxyribonucleotide di- and tri- phosphates across the mitochondrial matrix (53,54). In dividing cells, cytosolic dNTP pools are high and the mitochondria can access the cytosolic dNTP pools through the PNC carriers. However in resting cells, cytosolic dNTP pools drop and mitochondria depend on the mitochondrial TK2 and dGK. The availability of balanced dNTP pools within mitochondria is important for mitochondrial genome integrity and stability, and an imbalance interferes with normal mtDNA replication and repair processes leading to mtDNA depletion (55). Imbalances in dNTP pools may cause mutations in both mitochondrial and nuclear DNA and are associated with several human disorders including cancer (56).

### **3 MODELS TO STUDY GENETIC DISEASES**

#### **3.1 THE *Drosophila melanogaster* MODEL ORGANISM**

*Drosophila melanogaster* is one of the most commonly and intensively studied organisms in biology, especially in genetics. It has a short life cycle, and serves as a model to study several cellular and developmental processes that are common to higher eukaryotes. It has a small genome compared to humans with only 4 pairs of chromosomes (X/Y, II, III and IV) Most of the genetic information is present in chromosomes X, II and III (57). Approximately 60% of human disease genes are conserved in *Drosophila melanogaster* (58).

The mtDNA of *Drosophila melanogaster* is a 19.5 kb molecule and is similar to mammalian mtDNA, although with different gene arrangements. The non-coding region (NCR) in *Drosophila* mtDNA is an A+T rich region and it is of different size in different *Drosophila* subgroups (59).

In *Drosophila melanogaster*, four classes of DNA polymerases have been identified and characterized; pol- $\alpha$ ,  $\gamma$ ,  $\delta$  and  $\epsilon$ . Pol- $\alpha$ ,  $\delta$ , and  $\epsilon$  are involved in nDNA synthesis and function throughout nDNA replication and repair while pol- $\gamma$  is involved in mtDNA synthesis (60-63).

*Drosophila melanogaster* has a single multisubstrate deoxynucleoside kinase (*Dm*-dNK) that has the ability to catalyze the conversion of all four deoxynucleosides to their respective monophosphates (64,65). Cloning and characterization of *Dm*-dNK showed that this 29 kDa enzyme has high sequence similarity to mammalian TK2 and is closely related also to dGK and dCK (66,67). Preferred substrates for *Dm*-dNK are dThd, dUrd and dCyt,

but purine nucleosides are also efficiently catalyzed. *Dm*-dNK has 4-20,000 fold higher catalytic activity than mammalian dNKs, depending on the substrate (68).

### **3.2 THE MOUSE (*Mus musculus*) MODEL ORGANISM**

The past century has seen rapid development in use of laboratory mice as model organisms to study different areas of human diseases. Although yeast, worms and flies are exceptional models to study developmental biology and genetics, mice have served as better tools to study cardiovascular, nervous, immune, and other complex mammalian diseases. From immunosuppressed mouse models to humanized mouse models, there are thousands of different types of unique, exclusive and rare inbred and genetically modified strains that are used in almost every field of biological research.

Mice have 20 pairs of chromosomes (19 pairs autosomal, 1 X/Y pair) and the mouse genome was sequenced in 2002. The mouse genome is 14% smaller than the human genome; however over 80% of the mouse genes have a corresponding human counterpart (69). Both mice and humans have similar amounts of protein coding genes. Mouse mtDNA is highly homologous to human mtDNA, with respect to overall gene organization and sequence (70).

Common models to study human disease mechanisms are to use knockout, knockin or transgenic mice. Generation of knockout and knockin mouse models involve genetic manipulation of a specific locus in embryonic stem cells via homologous recombination. Knockout mice are generated by targeting a specific gene locus and rendering it non-functional by deleting or disrupting the gene. Knockout mice are commonly used to study human gene deficiencies. Knockin mice are generated by targeted insertion of a gene at a specific locus under the regulatory elements of another gene. Alternatively, transgenic mice are generated via random integration of a transgene construct into the mouse genome by injecting the transgene into the pronuclei. Both transgenic and knockin mouse models are used to study effects of gene overexpression. The expression of the transgene must be driven by its own strong promoter. Unlike homologous recombination, which is targeted integration into the genome, pronuclear injection causes random integration and variability in transgene copy number. (71,72).

## **4 MITOCHONDRIA**

Mitochondria, known as the ‘power house of the cells’, are complex, dynamic, semiautonomous, double-membraned organelles within almost all eukaryotic cells that provide energy through the process of oxidative phosphorylation (OxPhos). Evidence supports that billions of years ago, mitochondria were aerobic free living bacteria that were engulfed by a host cell, which has evolved to become the present day eukaryotic cell (73). Every cell has 10-1000s of mitochondria depending on the energy requirement of the cell. There are two pathways for ATP synthesis; glycolysis and OxPhos. Glycolysis involves breakdown of 6-carbon glucose to 3-carbon pyruvate. The pyruvate is converted to acetyl coenzyme A (acetyl CoA) which enters the mitochondria to participate in the tricarboxylic

acid cycle (TCA cycle) that produces the energy precursors for OxPhos. Electron carriers such as the reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH<sub>2</sub>), produced during glycolysis and the TCA cycle, are involved in transporting electrons from one component to another to generate ATP in the mitochondria. In addition, mitochondria have important roles in apoptosis, ageing, calcium signaling, iron-sulphur cluster assembly, iron metabolism and innate and adaptive immunity (74-82).

#### **4.1 MITOCHONDRIAL DNA DEPLETION SYNDROMES**

Human mtDNA is a circular double stranded DNA containing 16,569 bp encoding 37 genes; 13 protein coding genes, 22 transfer RNA coding genes and 2 ribosomal RNA coding genes (70,83,84). Various studies have contributed to the knowledge that mammalian mitochondria contain around 1,500 proteins that are expressed in a tissue specific manner (85,86). Since the mtDNA encodes only 13 of those proteins the mitochondria depend on nuclear DNA for all other proteins. The 13 protein encoding genes in the mitochondria encode enzymes involved in the OxPhos therefore an intact mtDNA is crucial for ATP production. Unlike nDNA, human mtDNA do not contain introns, and have almost the entire NCR concentrated in 1 region. The NCR contains elements for transcription and two origins of replication (87,88).

Mitochondrial DNA depletion syndromes (MDS) are clinically heterogeneous autosomal recessive disorders characterized by severe reduction in mtDNA levels (2,89,90). Mutations in nuclear encoded genes involved in the nuclear-mitochondrial crosstalk are also associated with mtDNA depletion syndromes (2,91). The mtDNA depletion may affect either a specific tissue or a combination of organs and tissues, including muscle, liver, brain and kidney (92). MDS manifestation can therefore be classified into four different forms: 1) myopathic, 2) hepatocerebral 3) encephalomyopathic and 4) neurogastrointestinal (2). Functional defects in any of the genes involved in mtDNA synthesis or maintenance results in mtDNA depletion. The most common cause of MDS are mutations in nuclear encoded *TK2*, *DGUOK*, *P53R2 (RRM2B)*, thymidine phosphorylase (*TYMP*), succinyl coenzyme A ligase alpha (*SUCLG1*) and beta (*SUCLA2*) subunits, enzymes that regulate dNTPs pools in the mitochondria (2). Additionally, defects in other proteins responsible for mtDNA replication and maintenance such as polymerase  $\gamma$  (*POLG*), the twinkle helicase (*CI0ORF2*), and mitochondrial inner membrane protein (*MPV17*) can also cause mtDNA depletion (2,91,93). MDS can be difficult to diagnose since many tissues can be simultaneously affected and the prevalence of MDS is unknown.

##### **4.1.1 Thymidine kinase 2**

Mitochondrial TK2 is encoded by the nuclear *TK2* gene (chromosome 16) and phosphorylates the pyrimidine deoxyribonucleosides, dThd, dUrd and dCyt to their respective monophosphates (25). TK2 deficiency is associated with a myopathic form of MDS (OMIM: #609560) (94). The first reports of children affected by TK2 deficiency had severe infantile myopathy and most often presented with gradual onset of hypotonia, fatigue, feeding

difficulties, proximal muscle weakness and loss of previously acquired motor skills (94-98). However, recent reports have identified milder forms of TK2 deficiency with adult onset and longer survival (99,100). TK2 deficiency can cause multi-organ mtDNA depletion with manifestation in muscle, brain and liver (101,102). Approximately 45-50 individuals have been reported with TK2 deficiency (103,104). Clinical diagnosis of TK2 deficiency includes multiple ragged red fibers, cytochrome C oxidase (COX) negative fibers, elevated serum creatine kinase levels and depletion of mtDNA content in the muscle biopsy sample (75-85%).

#### **4.1.2 Deoxyguanosine kinase**

Mitochondrial dGK is encoded by the nuclear *DGUOK* gene (chromosome 2) and phosphorylates the purine deoxyribonucleosides, dGuo and dAdo to their respective monophosphates (24). dGK deficiency is associated with the hepatocerebral form of MDS (OMIM: #251880) (105). Most of the individuals with *DGUOK* deficiency have severe multi-organ illness, with progressive liver damage, hypoglycemia, lactic acidosis and neurological damage (105-110). Approximately 100 individuals have been clinically diagnosed with *DGUOK* deficiency (110,111). The cytoplasmic enzyme dCK has overlapping substrate specificity with dGK phosphorylating dAdo, dGuo and dCyt in the cytoplasm (15,112). The tissue specificity of dGK deficiency is likely due to low expression of dCK in brain and liver tissues, which have a high demand of functioning mitochondria. Therefore these tissues depend on dGK for supply of precursors for mtDNA synthesis (105).

#### **4.1.3 Thymidine phosphorylase**

Thymidine phosphorylase is a cytosolic enzyme encoded by the nuclear *TYMP* gene (chromosome 22), which catalyzes the breakdown of dThd and dUrd to thymine or uracil respectively. The protein was initially identified as platelet-derived endothelial cell growth factor (113) and was thought to be specific to endothelial cells. Later on the *TYMP* gene expression was detected in other tissues with highest expression found in lung, brain, spleen and the digestive system, and relatively lower expression in kidney, muscle and fat (114). Additionally, the protein showed to have angiogenic activity in mouse tumors with 4-5 times higher expression in tumor cells than normal cells (113,114), and to catalyze the reversible dephosphorylation of thymidine to thymine (115).

Mutations in *TYMP* cause MDS manifesting as mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) (OMIM: #603041) (116). MNGIE is a progressive multisystem disorder characterized by severe ptosis, progressive external ophthalmoplegia (PEO), gastrointestinal dysmotility, cachexia, diffuse leukoencephalopathy, peripheral neuropathy, ragged-red fibers or increased succinate dehydrogenase activity in muscle biopsy, and mitochondrial dysfunction caused by mtDNA depletion, deletions and point mutations (116-118). Severe impairment of the *TYMP* enzyme causes increased accumulation of plasma thymidine which disturbs the mitochondrial dNTP pool balance leading to mtDNA abnormalities (119).

#### 4.1.4 P53 inducible subunit of ribonucleotide reductase

The P53 inducible ribonucleotide reductase small subunit (P53R2) is encoded by the nuclear *RRM2B* gene (chromosome 8) that forms a functional RNR with the R1 subunit and catalyzes the conversion of NDPs to dNDPs (34,120). Human cancers are frequently characterized by inactivation of the P53 gene, that in a normal cell acts as a tumor suppressor by regulating the cell cycle or inducing apoptosis (33). The P53R2 subunit has high sequence similarity with the R2 subunit of the RNR, and has a crucial role in regulating dNTP synthesis during DNA damage (34,37,121). *RRM2B* was shown to be constitutively expressed in low amounts in proliferating and resting cells (36).

*RRM2B* is ubiquitously expressed in human tissues with high expression in skeletal muscle. *RRM2B* gene mutations primarily cause myopathy (OMIM: #612071), characterized by severe mtDNA depletion (1-10% of controls) ragged red fibers and COX negative staining, but also affects kidney and brain (122-125).

#### 4.1.5 Succinyl coenzyme ligase subunits $\alpha$ and $\beta$

Succinyl coenzyme A synthetase, also known as succinate coenzyme A ligase (SUCL), is a mitochondrial TCA cycle enzyme that catalyzes the reversible reaction between succinyl coenzyme A and succinate. Succinyl CoA is important for activation of ketone bodies and heme synthesis. There are two isoforms of SUCL; an ATP-specific isoform (SUCLA) and a GTP-specific isoform (SUCLG) catalyzing ATP and GTP dependent reactions respectively (126).

SUCL proteins are composed of 2 subunit types; an  $\alpha$ -subunit encoded by *SUCLG1* and a  $\beta$ -subunit encoded by either *SUCLA2* or *SUCLG2* that determines the nucleotide specificity of the enzyme (126-129). The  $\beta$ -subunits are expressed in most human tissues with *SUCLA2* being predominantly expressed in brain and muscle and *SUCLG2* in liver and kidney. *SUCLG1* is ubiquitously expressed with highest expressions in brain, heart, kidney and liver (126,129,130). Mutations in *SUCLA2* and *SUCLG1* are associated with hepatoencephalomyopathic forms of MDS (with methylmalonic aciduria) (OMIM: #245400) (131). Deficiency of *SUCLA2* results in Leigh's or a Leigh-like syndrome with onset of severe hypotonia before the age of 6 months. Affected children develop sensorineural hearing impairment, psychomotor delay, and severe muscular atrophy (132). Most patients die in childhood, and metabolic analysis consistently shows elevated levels of plasma and urine methylmalonic acid (128,133-136). Mutations in *SUCLG1* causes fatal infantile lactic acidosis and affects the liver (40% of the patients), manifesting as hepatomegaly, steatosis, and liver failure (129,137-139). 15% of patients with *SUCLG1* mutations also present with hypertrophic cardiomyopathy (129). Approximately 70 patients with *SUCLA2* and *SUCLG1* mutations have been clinically diagnosed so far (129).

#### 4.1.6 Polymerase gamma

DNA polymerase gamma (pol  $\gamma$ ) plays an important role in mitochondrial DNA replication and repair (140). Human pol  $\gamma$  is highly expressed in skeletal muscle and heart

tissues (141). The pol  $\gamma$  holoenzyme contains two subunits; the catalytic subunit encoded by the nuclear *POLG* gene that has DNA polymerase, 3'-5' exonuclease and 5'-deoxyribose phosphate lyase activities, and an accessory subunit encoded by the nuclear *POLG2* gene that participates in DNA binding and DNA synthesis (142-144).

Over 200 mutations in *POLG* have been identified that are associated with Alpers-Huttenlocher syndrome, childhood myocerebrohepatopathy spectrum disorders, myoclonic epilepsy myopathy sensory ataxia, ataxia neuropathy spectrum of syndromes and PEO (OMIM: #203700, #613662) (reviewed in (145,146)). Multiple tissues such as liver, skeletal muscle and brain are affected and have been shown to have mtDNA depletion. The onset of the clinical phenotype can vary from early infantile to late adult onset as in the case of PEO and ataxia neuropathy syndromes (147).

#### **4.1.7 Twinkle helicase**

Twinkle is a mitochondrial protein encoded by the nuclear *C10ORF2* gene (chromosome 10 open reading frame 2). Twinkle was identified as a T7 phage helicase like protein, and the name derives from the localizing pattern resembling twinkling stars (148). Mutations in *C10ORF2* are associated with a hepatocerebral form of MDS (OMIM: #271245) and cause autosomal dominant PEO (adPEO) and infantile-onset spinocerebellar ataxia (148,149). Common clinical features of adPEO include hearing loss, proximal muscle weakness, ptosis, ophthalmoplegia and sensory axonal neuropathy (150). Some patients with late onset PEO also developed dementia in their late seventies (151). The spinocerebellar ataxia phenotype was characterized by severe mtDNA depletion in brain and liver, progressive cerebellar atrophy, sensory axonal neuropathy, severe neonatal hypotonia increased serum lactate levels, seizures and peripheral neuropathy (152,153).

#### **4.1.8 MPV17**

*MPV17* is a human gene that encodes a mitochondrial inner membrane protein, believed to play a role in the metabolism of reactive oxygen species (ROS) (154). The MPV17 protein is expressed in human liver, heart, kidney, skeletal muscle, lung, brain, pancreas and placenta (155). *MPV17* mutations were initially identified as Navajo neurohepatopathy, where affected children presented with sensorimotor neuropathy, spinal cord atrophy, corneal ulceration, acral mutilation, progressive central nervous system white matter lesions and liver disease (156,157). Mutations in *MPV17* is associated with hepatocerebral forms of MDS (OMIM: #256810), characterized by progressive liver failure, often affecting children within their first year of life (154,155,158,159).

#### **4.1.9 Other genes causing MDS**

The clinical spectrum of MDS is expanding and new genes and novel mutations in previously described genes are constantly emerging. Several new genes have been identified whose mutations cause severe mtDNA depletions and mtDNA deletions (OMIM: #212350; #615084; #616896; #615471). Mutations in acylglycerol kinase (a mitochondrial membrane

protein involved in lipid and glycerolipid metabolism), mitochondrial genome maintenance exonuclease 1 gene, mitochondrial dynamin like GTPase, mitochondrial F-box, leucine-rich repeat 4 protein, and mitochondrial transcription factor A have recently been associated with cardiomyopathic, encephalomyopathic and hepatocerebral forms of MDS (160-166).

## 4.2 ANIMAL MODELS FOR MDS

Animal models are important tools to develop treatments for rare diseases particularly when only small populations of patients are available to evaluate the disease. The use of animal models helps unveil the natural history of the disease, its etiology and characteristics. Modelling mitochondrial dysfunction and mtDNA depletion syndrome is particularly difficult due to the unique mitochondrial genetics. Different animal models, mainly mouse and rats, have been generated to study MDS with the aim to gain mechanistic insights and to develop therapeutic strategies.

**TK2 deficiency:** Two different mouse models have been generated for TK2 deficiency; a knockin mouse model with the amino acid substitution H126N, corresponding to the human pathogenic mutation H121N (167), and a *Tk2* knockout mouse model with a deletion of exon 4 and part of exon 5, which encodes for the substrate binding domain of the enzyme active site (168). Both the *Tk2* deficient mouse models, despite the genetic differences, had normal growth at birth, and progressive growth decline from postnatal day 7 to 10. Both models displayed encephalomyopathy and neurological involvement caused by severe mtDNA depletion in the brain, and died prematurely within 2-4 weeks of age (167-169). The *Tk2* knockout mice had severe hypothermia and loss of hypodermal fat. A mtDNA depletion was observed in adipose tissues, causing alterations in brown and white adipose tissue development (170). Tissue specificity and onset of TK2 deficiency has been attributed to transcriptional compensation of TK1 (171). Gradual depletion of mtDNA in mouse liver was also observed (up to 80% reduction by postnatal day 14), that was accompanied by increased mitochondrial volume, altered mitochondrial structure in the liver, reduced mitochondrial  $\beta$ -oxidation and accumulation of lipid vesicles in the liver cells (172).

**dGK deficiency:** A rat model for dGK deficiency was reported recently (173). The *Dguok* deficient rats were generated using zinc finger nuclease technology that generated 3 knockout rat lines with varied base pair deletions causing approximately 90% reduction in hepatic mtDNA in these rats. The mtDNA depletion was also observed in spleen although to a lesser extent (60% of control). Muscle had no reduction in mtDNA content but had 20-30% COX negative fibers, and reduced complex I and III protein expressions. Electron paramagnetic (spin) resonance spectroscopy technique was applied to characterize respiratory chain abnormalities in the dGK deficient rats (173). The rats did not show a MDS phenotype suggesting a remaining dGK activity in this rat model.

**TYMP deficiency:** A knockout mouse model with targeted deletion of both thymidine and uridine phosphorylase (*Tymp*<sup>-/-</sup>*Upp*<sup>-/-</sup>) showed hyperintense brain lesions and axonal swelling



indicative of mitochondrial leukoencephalopathy (174). Increased levels of dThd, Urd and dUrd were measured in plasma and several tissues including skeletal muscle, brain, kidney and heart of *Tymp<sup>-/-</sup>Upp<sup>-/-</sup>* mice (175). The severe progressive mtDNA depletion in these mice is due to unbalanced dNTP pools caused by *Tymp Upp* deficiency, and reflects the MNGIE patient phenotype (175,176).

**P53R2 deficiency:** *Rrm2b* knockout mice were generated by deleting exon 3 and 4 of the *Rrm2b* gene. *Rrm2b*-deficient mice appeared normal at birth and displayed progressive growth retardation from 6 weeks of age, followed by premature death due to renal failure (approximately 12 weeks) (177). The renal failure in *Rrm2b*-deficient mice is caused by alterations of dNTP pools causing oxidative stress and increased spontaneous mutations (177). Other organs including heart, skeletal muscle, liver and nerve fibers also underwent atrophic changes.

**POLG deficiency:** Several mouse models have been generated with modified *Polg*. *PolgA* knockout mice showed early developmental arrest between embryonic day E7.5-8.5 associated with severe mtDNA depletion (178). Transgenic mice with specific cardiac tissue targeted mutants of human Pol  $\gamma$ , (Y955C point mutation), caused chronic PEO in the heart, with cardiomyopathy, mitochondrial oxidative stress and structural damage, pathological cardiomegaly, and premature death (179). *PolG2* mutations are known to cause adPEO. A *Polg2* knockout mouse model, generated to better understand the functions of POLG2, resulted in embryonic lethality (E8.0-8.5) with mtDNA depletion and mitochondrial ultrastructural defects (180). Several other mouse models for *Polg* mutations have been developed and extensively studied. These “Mutator mice” have impaired 3’-5’ exonuclease activity thereby causing accumulation of mtDNA deletions and point mutations leading to OxPhos deficiency, and a premature ageing phenotype (181-186).

**SUCLA2 and SUCLG1 deficiency:** Transgenic mice were generated using a mutant allele of *Sucla2* isolated by FACS-based retroviral-mediated gene trap mutagenesis screen that identified abnormal mitochondrial phenotypes in mouse ES cells (187). Homozygotes with mutant *Sucla2* transgene were embryonically lethal (E18.5) with varying mtDNA depletion in embryonic brain, heart and muscle tissues (20-60% of control). Currently there is no animal model reported with *Suclg1* deficiency.

**Twinkle helicase deficiency:** A conditional gene knockout mouse model for *Twinkle* helicase has been developed (188). Loss of *Twinkle* caused embryonic lethality (approximately E8.5), while tissue specific disruption of *Twinkle* in heart and skeletal muscle tissues caused premature death (approximately 19 weeks) with severe progressive mtDNA depletion and profound respiratory chain dysfunction in heart tissue (188). Earlier studies have shown that mouse models overexpressing mutant forms of *Twinkle*, commonly named as the “Deletor mice” showed adPEO and late onset mitochondrial disease with

mitochondrial myopathy, abnormal skeletal muscle fiber size, COX negative fibers, accumulation of deleted mtDNA and mtDNA depletion (189-191).

**MPV17 deficiency:** *Mpv17* knockout mice (*Mpv17*<sup>-/-</sup>) were developed and showed profound mtDNA depletion in the liver (154). A mtDNA depletion was also observed in skeletal muscle to a lesser extent, but not in kidney and brain tissues up to 1 year of age. However, 18 months and older mice developed focal segmental glomerulosclerosis with high proteinuria, and severe mtDNA depletion in glomerular tufts (192). dNTP pools measured in liver, brain and kidney mitochondria of *Mpv17*<sup>-/-</sup> mice showed marked decrease in the liver dTTP and dCTP pools causing severe mtDNA depletion, while brain and kidney dNTP pools remained unaltered. MPV17 is therefore believed to regulate the mitochondrial nucleotide salvage pathway (193).

### 4.3 CANCER CELL METABOLISM

Cells convert the biochemical energy from nutrients to ATP, a process known as cellular respiration. Cellular ATP is produced via two interconnected pathways; glycolysis (an anaerobic pathway) and OxPhos (an aerobic pathway). Under aerobic conditions, glucose is broken down to pyruvate in the cytosol, which is then converted into acetyl coenzyme A (acetyl CoA) in the mitochondrial matrix, catalyzed by pyruvate dehydrogenase. The acetyl CoA enters the tricarboxylic acid cycle (TCA cycle or Krebs cycle or citric acid cycle) within the mitochondrial matrix where it is oxidized to carbon dioxide. The TCA cycle generates electron carriers such as NADH and FADH<sub>2</sub> that transfer electrons to the mitochondrial respiratory chain (MRC) complexes to generate ATP via OxPhos. Under anaerobic conditions, the pyruvate is fermented to form lactate.

Cancer cells are cells that undergo uncontrolled cell division due to activation or suppression of genes involved in regulating cell growth. One of the features of cancer cell metabolism is the increased preference for glycolysis over OxPhos, even in the presence of oxygen, a process known as aerobic glycolysis or the Warburg effect (194). In order to compensate for the metabolic reprogramming, cancer cells take up higher amounts of glucose and increase lactate production. Glycolysis contributes to more than just ATP synthesis in a cell. Intermediates from the glycolysis and the TCA cycle are essential for several anabolic pathways such as the pentose phosphate pathway and the synthesis of fatty acids, cholesterol, glycogen, glycerol and amino acids (figure 3).




Figure 3: Glucose metabolism in quiescent and dividing cells. Reprinted with permission from Elsevier (195).

Cancer is driven by several factors such as activation of oncogenes, loss of tumor suppressors and mutations in the nDNA or the mtDNA affecting the MRC complexes. Beyond energy production, mitochondria influence cancer metabolism and tumorigenesis in many different ways including to maintain redox homeostasis, to regulate apoptosis, to regulate cellular metabolites and the signaling processes (196).

Alterations in cellular metabolism occur during tumorigenesis to facilitate cell survival and growth. Studies on metabolic profiling of cancer cells have shown that numerous metabolic enzymes and metabolites have tumor specific changes in expression profiles (197-199). Activities of these enzymes and metabolites are a tightly regulated network within the cell and any disturbance may cause cascading effects on the network contributing to the malignant phenotype. Therefore, to target metabolic pathways is important to understand the regulation of metabolic reprogramming in cancer.

#### 4.3.1 Mitochondrial solute carriers

Healthy cells depend on the finely tuned channeling of metabolic substrates and products across subcellular compartments by a number of transporters (200). The mitochondria host several transporters that facilitate transport of substrates across the mitochondrial membrane. The outer mitochondrial membrane contains voltage dependent anion channels, and is relatively permeable, while the inner mitochondrial membrane is highly impermeable in order to maintain efficient OxPhos. The mitochondrial carriers are a family of nuclear encoded proteins called the solute carrier family 25 (SLC25). The SLC25

proteins are localized in the impermeable mitochondrial inner membrane and are essential for effective mitochondrial–cytosolic crosstalk. The SLC25 transporters consists of 53 members that are involved in transport of molecules in several metabolic pathways such as the TCA cycle, the urea cycle, the OxPhos, the gluconeogenesis, the fatty acid oxidation, the amino acid degradation, the maintenance of dNTP pools, the calcium signaling and the iron metabolism (200,201). Based on their substrate the transporters can be broadly classified into different clades as amino acid carriers, nucleotide carriers, uncoupling protein carriers and carboxylate carriers (201).

The mitochondrial SLC25 member 10 (SLC25A10) is a dicarboxylate carrier that transports TCA cycle intermediates between the cytoplasm and the mitochondria (202). The carrier transports dicarboxylates such as malate or succinate across the mitochondrial membrane in exchange for phosphates, succinate and thiosulphates (203-206). In humans, SLC25A10 is highly expressed in liver and kidney tissues, where it plays a major role in gluconeogenesis, the urea cycle and sulphur metabolism (207). In mice, predominant expression of the dicarboxylate carrier is observed in white adipose tissue with a role in fatty acid biosynthesis (208). Fatty acid synthesis occurs in the cytosol and is initiated by the export of citrate from the mitochondria to the cytosol by a mitochondrial citrate carrier SLC25A1 (209) (figure 4).




Figure 4: Schematic representation of the SLC25A10 carrier in cell metabolism. Enzymes are represented in green; GDH-glutamate dehydrogenase, LDH-lactate dehydrogenase, MDH-malate dehydrogenase, ME1-malic enzyme 1, PC-pyruvate carboxylase.

SLC25A10 has been shown to transport malate into the mitochondria during the citrate transport to the cytoplasm required for fatty acid synthesis. Inhibition of the SLC25A10 carrier was shown to reduce lipid accumulation in adipose tissues (202). Additionally, SLC25A10 plays a role in the regulation of glucose-stimulated insulin secretion in pancreatic beta cells (210). Overexpression of the SLC25A10 carrier in a human embryonic kidney cell line resulted in hyperpolarization of the mitochondria (208), and overexpression in adipocytes resulted in increased ROS production (211). The dicarboxylate carrier along with the mitochondrial 2-oxoglutarate carrier facilitates glutathione transport from the cytosol to the mitochondria (212,213). Together, these studies show that the SLC25A10 carrier plays an important role not only in providing substrates for several biosynthetic pathways but also in regulating redox homeostasis.

## 5 TREATMENT STRATEGIES FOR MITOCHONDRIAL DYSFUNCTION

Mitochondrial dysfunction and subsequent OxPhos defects are characteristic of many neurological diseases such as Alzheimer's and Parkinson's disease, diabetes, ageing, cancer and the different forms of mitochondrial diseases that arise due to dysfunctional respiratory chain complexes (214-216). Multiple tissues are affected by defects in the mitochondria, especially tissues that have a high energy demand such as skeletal muscle and brain. Reduction of the metabolic load by dietary manipulation, enzyme replacement, removal of toxic metabolites and organ transplantation are some of the therapeutic approaches for mitochondrial diseases (reviewed in (217)). The mtDNA are constantly subjected to damage due to ROS production within the mitochondria. Studies using dichloroacetate, creatine, coenzyme Q<sub>10</sub>, antioxidants and lipoic acid have been investigated in patients with mitochondrial diseases (217). The heterogeneity of mitochondrial disorders makes it a challenging task for development of therapeutic approaches.

Currently there are no proven effective treatments for MDS. Care and management of MDS include supportive treatments with vitamins and cofactors, but with poor efficacy. Liver transplantation has shown to improve quality of life in some patients with *POLG1*, *DGUOK* and *MPV17* mutations. However, liver transplantation alone is in most cases not sufficient since the disease manifestations are multisystemic and also involve severe neurological symptoms (159,218-221). A controlled diet avoiding hypoglycemia or a lipid rich diet together with succinate and coenzyme Q<sub>10</sub> have shown to delay progression of liver disease in some patients with *MPV17* mutations (222,223). Enzyme replacement therapy using allogenic stem cell transplantation and continuous ambulatory peritoneal dialysis have shown promising effects in MNGIE patients (224-227). *In vitro* studies have demonstrated that supplementation of medium with dAMP and dGMP in patient derived dGK deficient quiescent fibroblasts could partially restore the mtDNA depletion (228,229). Recently, studies have shown that oral supplementation of deoxypyrimidine monophosphates (dTMP and dCMP) was able to prolong the lifespan and delay disease onset in a *Tk2*<sup>-/-</sup> knockin

mouse model (230). The effect correlated with the dose of administration and an increase in mtDNA copy number and respiratory chain activities were observed in brain, heart, skeletal muscle, kidney and liver in these mice (230). Gene therapy approaches using adeno associated virus and lentiviral vectors have been studied in mouse models for ethyl malonic encephalopathy and the MNGIE form of MDS (231,232).

Current therapies for cancer include radiation and chemotherapy that have adverse effects on all cells. Targeted therapy is a newer type of cancer therapy that specifically targets cancer cells with potentially less side effects on normal healthy cells. There is a need for additional treatment strategies to make rational combination approaches possible. With the development of inhibitors of metabolic enzymes it could be possible to target the metabolic reprogramming in cancer cells. Characteristics of cancer cells are upregulated glycolysis and increased lactate production. Many compounds targeting key metabolic enzymes, intermediates and transporters of the glycolytic pathway are exploited for development of therapeutic strategies (233-235). Glutamine is a multifunctional metabolite that is involved in energy production, synthesis of macromolecules and regulation of redox homeostasis. Several cancer types such as the ones driven by Myc and Kras mutations are highly sensitive to glutamine deprivation (236,237). Approaches that target the different roles of glutamine metabolism and dependency have been studied (reviewed in (238)). Antioxidants are important to regulate ROS mediated mitochondrial damage and are explored as possible anticancer agents. Cancer cells increase their antioxidant capacity to prevent buildup of ROS. The reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) generated in the cytosol primarily via the pentose phosphate pathway, is involved in maintaining the antioxidant defense systems by quenching the ROS produced during rapid cell proliferation. NADPH donates electrons for the ROS scavenging systems including glutathione and thioredoxin (239). *In vitro* studies have demonstrated that targeting enzymes that regulate redox balance are effective against certain cancers cell lines (240-242).

The importance of mitochondria and mtDNA depletion for tumorigenesis and metastasis has several implications in terms of future cancer treatment including identification of selective drug targets and development of new intervention strategies. To understand the regulation of cancer metabolism could serve as a platform to design and predict the efficacy of different therapies.

## **6 AIM OF THE PRESENT WORK**

The aim of the present study was

- to get mechanistic insights in the mitochondrial dysfunction caused by TK2 deficiency
- to elucidate possible treatment strategies for TK2 deficiency and other mitochondrial disorders
- to investigate the mitochondrial carrier, SLC25A10 and its role in cancer cell metabolism and in the regulation of redox homeostasis.

## 7 REFLECTION ON THE METHODOLOGY

In general, most of the methods used in this thesis are well established methods. Cell culture techniques, DNA, RNA and protein extraction protocols, genotyping using polymerase chain reaction (PCR), Western blot for protein expression studies, and quantitative real time PCR (qPCR) (both TaqMan and SYBR green techniques) for gene expression profiling, are all described in detail in papers I, II, III and IV. Microscopic analysis of mouse tissues using histopathology, immunohistochemistry and electron microscopy was performed at the Department of Laboratory Medicine, Division of Pathology, Karolinska Institute. Several kits used in all four papers are listed in table 2.

Table 2: List of kits used in the thesis

Method	Kit	Company
DNA extraction	DNeasy blood and tissue kit	Qiagen
PCR	GoTaq G2 Flexi DNA Polymerase	Promega
	PfuUltra high fidelity DNA polymerase	Agilent
RNA extraction	RNeasy mini kit	Qiagen
cDNA synthesis	high capacity cDNA reverse transcription kit	Applied Biosystems
qPCR	TaqMan universal qPCR mix	Applied Biosystems
	KAPA SYBR Fast qPCR kit	KAPA Biosystems
	ABI 7500 Fast Machine	Applied Biosystems
siRNA vector	pSilencer <sup>TM</sup> Puro Expression Vectors kit	Applied Biosystems
siRNA transfection	Fugene 6 HD kit	Promega
NADP/NADPH assay	NADP/NADPH assay kit	Abcam
XTT assay	Cell proliferation assay kit II	Roche Life Science

### 7.1 TRANSGENE CONSTRUCTS

The *Dm-dNK* transgene construct was generated using the previously cloned *Dm-dNK* cDNA (66). The 850 bp open reading frame sequence was ligated to a pcDNA3 vector with mouse cytomegalovirus (CMV) promoter region (paper I and II) and with mouse albumin promoter (paper III). A 6-histidine tag was fused to the C-terminal of the *Dm-dNK* sequence in both constructs. The transgene constructs were digested from pcDNA3 vector using *Bgl*III and *Dra*III, and *Sna*BI and *Dra*III restriction enzymes for CMV-*Dm-dNK* and albumin-*Dm-dNK* constructs respectively. The two transgenic constructs are shown in figure 5.






Figure 5: *Dm-dNK* transgenic constructs. (a) CMV-*Dm-dNK* transgenic construct, (b) albumin-*Dm-dNK* transgenic construct

## 7.2 MICE

Wild type (C57BL6/N) mice from Charles River Laboratories were used in this thesis. Two different transgenic mouse strains have been generated; CMV-*Dm-dNK* and albumin-*Dm-dNK*. The CMV-*Dm-dNK* mice were intercrossed with the previously described *Tk2* knockout mice (*Tk2*<sup>-/-</sup>) (168) to generate *Dm-dNK*<sup>+/-</sup>*Tk2*<sup>-/-</sup> mouse strain. These mice were used to study whether transgenic *Dm-dNK* expression was able to rescue *Tk2* deficiency in mice. The albumin-*Dm-dNK* mice will serve as a tool to study whether tissue specific expression of *Dm-dNK* is able to rescue *Tk2* deficiency in mice.

All mice were housed and bred at the Karolinska Institute, Division of Comparative Medicine, Clinical Research Center, Huddinge. All animal procedures were compliant with the Swedish Board of Agriculture (Jordbruksverket) animal research ethical regulations (ethical permits S135-11, S6-13, S100-15). Transgenic mice were generated using pronuclear injection technique performed at the Division of Comparative Medicine, Clinical Research Center, Huddinge for CMV-*Dm-dNK* mice and Karolinska Center for Transgenic Technologies (KCTT), Solna for the albumin-*Dm-dNK* mice.

## 7.3 MITOCHONDRIAL DNA COPY NUMBER

To study the effect of *Dm-dNK* in *Tk2* deficient mice, mtDNA copy number was measured in several tissues of wild type and *Dm-dNK* expressing mice. Total DNA was extracted from mouse tissues and mtDNA copy number was performed using qPCR. Specific TaqMan primers and probes were designed for a nuclear encoded ribonuclease P RNA component H1 (*Rpph1*), and mitochondrial encoded NADH dehydrogenase 1 (*mt-ND1*). mtDNA was quantified using standards that were prepared using the pGEMT plasmid containing one copy each of the mouse *Rpph1* and *mt-ND1* genes. The mtDNA copy number was measured in skeletal muscle, brain and liver of all mice (paper I and II).

## 7.4 MEASUREMENT OF dNTP POOLS

dNTPs were extracted from whole cell extracts (paper I and II) and mitochondria (paper II) using MTSE buffer and methanol (described in detail in paper I). dNTP measurement was performed by a DNA polymerase based assay using templates and primers designed specifically for the different dNTPs measured. (243). The technique is based on

incorporation of tritium labelled dATP ( $^3\text{H-dATP}$ ) (for measuring dTTP, dCTP, dGTP pools) or  $^3\text{H-dTTP}$  (for measuring dATP pools) into a template oligonucleotide via primer extension. The DNA polymerase used for this reaction is the Klenow subunit of *E.coli* polymerase I, known as the Klenow polymerase. The assay was carried out by incubating extracts containing unknown amounts of all 4 dNTPs with the Klenow polymerase, tritiated dNTP and a template specific for the dNTP to be measured, with a known repetitive deoxyribonucleotide sequence. The reaction was incubated for 30-45 min, spotted on Whatman DE-81 filter discs and washed with  $\text{Na}_2\text{HPO}_4$ , water and ethanol. The retained radioactivity was measured by scintillation counting using beta counters. In paper I, dCTP, dTTP and dGTP pools were determined using this technique. It was not possible to measure dATP pools because, *Dm-dNK* expression causes a large increase in dTTP pool which affects the dATP pool measurements. In paper II, a modified template strand was synthesized for measurement of the dATP pools.

## 7.5 MUTATION ANALYSIS

The mtDNA are known to have higher acquired mutation rates than nDNA due to constant exposure to ROS, lack of histones and inefficient DNA repair mechanisms (244). The mitochondrial NCR is a hotspot for mutagenic effects in mtDNA as it contains two hypervariable regions. To sequence the mitochondrial NCR is therefore a great tool to study mtDNA mutation frequencies. Expression of *Dm-dNK* in mouse tissues causes increase in all four dNTP pools, particularly dTTP. Analysis of mtDNA point mutations in mitochondrial NCR and cytochrome b (*Cytb*) gene was performed to study the effect increased dTTP pools in *Dm-dNK*<sup>+/-</sup> mice (paper I). Total DNA was extracted from skeletal muscle of wild type and *Dm-dNK*<sup>+/-</sup> mice using DNeasy kit (Qiagen). Fragments of the *mt-NCR* and *mt-Cytb* were amplified using high-fidelity PCR and cloned into the pGEM-T vector (Promega) according to manufacturer's instructions. Multiple clones obtained were sequenced, and point mutations and mutation frequencies were calculated.

Mutation frequencies were measured in the well characterized hypoxanthine-guanine phosphoribosyl transferase encoded by the *HPRT* gene. The *HPRT* gene locus has been used as a tool for mutagenesis studies for many years owing to the fact that a wide range of mutations are associated with it. In order to detect point mutations in the *Hprt* exon sequence, the mouse *Hprt* mRNA and corresponding cDNA was used as starting point of the sequencing analysis (paper II). mRNA was extracted from skeletal muscle of 12 month old wild type and *Dm-dNK* expressing mice (both *Dm-dNK*<sup>+/-</sup> and *Dm-dNK*<sup>+/-</sup>*Tk2*<sup>-/-</sup>), and cDNA synthesis was performed using high capacity cDNA reverse transcription kit (Applied Biosystems). Fragments of mouse *mt-Cytb* gene and *Hprt1* gene were amplified using high-fidelity PCR, from cDNA template. The PCR amplicon fragments were cloned to pGEM-T vector (Promega) according to manufacturer's instructions. Multiple clones obtained were sequenced, and point mutations and mutation frequencies were calculated.

## 8 BRIEF SUMMARY OF RESULTS

Paper I, II and III (manuscript) focus on therapeutic approach for mitochondrial DNA depletion syndrome caused by TK2 deficiency. Paper IV focuses on the role of mitochondrial carriers in cancer cell metabolism and for the regulation of the redox balance in cells. A brief summary of the results is presented below.

### 8.1 PAPER I

#### **Transgene expression of *Drosophila melanogaster* nucleoside kinase reverses mitochondrial thymidine kinase 2 deficiency**

The life span of *Tk2* knockout mice ( $Tk2^{-/-}$ ) is approximately 3-4 weeks. These mice die due to severe mtDNA depletion in multiple organs. In an attempt to rescue the severe mtDNA depletion caused by TK2 deficiency, transgenic mice expressing the deoxynucleoside kinase from *Drosophila melanogaster* (*Dm-dNK*<sup>+/+</sup>) driven by the CMV promoter were generated. These mice were crossed with  $Tk2^{+/-}$  mice to get *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>+/+</sup> mice, which were then intercrossed with *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>+/+</sup> mice to obtain *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup> mice. The *Dm-dNK* expressing mice (*Dm-dNK*<sup>+/+</sup> and *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup>) were characterized for a period of 6 months. *Dm-dNK* activity was the highest in skeletal muscle and kidney and lowest in liver and heart tissues and was found to be constantly expressed up to the age of 6 months. No difference in mtDNA copy number was observed in skeletal muscle of wild type and *Dm-dNK* expressing mice. *Dm-dNK* expression resulted in very high dTTP levels (>100 fold) and slightly high dCTP and dGTP levels (approximately 3 and 1.5 fold respectively) in the skeletal muscle extracts of *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup> mice in comparison to wild type mice. There were no major histopathological difference observed in skeletal muscle and liver. Mutation analysis of *mt-Cytb* and *mt-NCR* revealed no significant differences in *Dm-dNK* expressing mice compared to wild type mice.

### 8.2 PAPER II

#### **Long term expression of *Drosophila melanogaster* nucleoside kinase in thymidine kinase 2 deficient mice with no lethal effects caused by nucleotide pool imbalances**

In order to study the long term effects of *Dm-dNK* transgene in mice, the *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup> mice were studied for their growth and behavior for a period of 20 months. During this period the *Dm-dNK* transgene was constantly expressed. There was a significant decrease in total body weight of the *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup> mice compared to wild type mice due to decrease in subcutaneous and visceral fat, likely due to the low enzyme activities in some tissues such as liver, heart and adipose tissues. Expression of *Dm-dNK* resulted in increase in all four dNTP levels with dTTP being the highest. This increase in dTTP pools did not cause any significant point mutations in the nuclear or mitochondrial DNA. There was a slight decrease in mtDNA copy number in the *Dm-dNK*<sup>+/+</sup> $Tk2$ <sup>-/-</sup> mice compared to wild type or *Dm-dNK*<sup>+/+</sup> mice at 12 months of age, however this difference was not observed at 18 months. Electron microscopy of the kidney and muscle did not show any changes in the mitochondrial density or structure.

A slight increase in mRNA levels of thymidine phosphorylase enzyme was observed in the *Dm-dNK* expressing mouse tissues, while all other dNTP metabolizing enzymes were similar to wild type mRNA levels. The decrease in body fat was observed only in *Dm-dNK<sup>+/-</sup>Tk2<sup>-/-</sup>* mice and not in control *Dm-dNK<sup>+/-</sup>* mice, therefore it is likely to be an effect of lack of *Tk2* and lower expression of *Dm-dNK* in the adipose tissues.

### **8.3 PAPER III (MANUSCRIPT)**

#### **Construction of a mouse strain with liver specific expression of *Drosophila melanogaster* nucleoside kinase**

The *Dm-dNK* transgene driven by the CMV promoter could rescue *Tk2* knockout mice, and restore mtDNA depletion caused by *Tk2* deficiency. This study aims to investigate whether *Dm-dNK* expressed solely in the liver would be sufficient to rescue mtDNA depletion caused by deoxynucleoside kinase deficiency. A mouse model was constructed to express *Dm-dNK* specifically in liver tissue driven by the liver specific albumin promoter. 8 out of 50 founder mice (16%) genotyped had the *Dm-dNK* transgene integrated along with the albumin promoter. Only 2 out of 8 positive founder mice had a higher *Dm-dNK* expression (approximately 2.5 times) compared to wild type control. *Dm-dNK* expression was measured both in mRNA level using quantitative real time PCR and in protein level using enzymatic assays. The two founder mice were selected for further studies based on high expression of *Dm-dNK* in liver and low expression in other tissues.

### **8.4 PAPER IV**

#### **The mitochondrial carrier SLC25A10 regulates cancer cell growth**

SLC25A10, the mitochondrial dicarboxylate carrier, was knocked down in A549 cells using the siRNA technique. Our results show that knockdown of SLC25A10 in A549 cells changed the growth properties to a less malignant phenotype, with small cell size, monolayer growth and polarized mitochondrial formation around the nucleus. SLC25A10 knockdown cells had a higher dependency on glutamine, and an increased sensitivity to oxidative stress. In dividing cells, knockdown of SLC25A10 caused decreased NADPH/total NADP ratio compared to control cells, in cells grown in both glutamine and glutamine free medium. Gene expression of several genes involved in maintenance of redox homeostasis, metabolic and regulatory enzymes and some genes involved in cancer signaling pathways were analyzed using qPCR. Gene expression of *TXN2* and *TXNRD2* were downregulated while gene expression of *GLUD2*, *LDHA*, and *PDHA1* were upregulated in dividing siRNA knockdown cells compared to control cells. In confluent cells, gene expression of *TXN2*, *LDHA* and *LDHB* were downregulated and gene expression of *TXN*, *TXNRD1*, *GLUD1* and *GLUD2* were up regulated, in siRNA knockdown cells compared to control cells. A decrease in protein expression, measured using Western blot, of some proteins involved in cancer signaling pathways such as p53, HIF1 $\alpha$ , and p21 was observed in siRNA knockdown cells compared to control cells.

## 9 CONCLUDING REMARKS

A *Tk2* deficient mouse model expressing *Dm-dNK* transgene was established and characterized. Transgene expression of *Dm-dNK* reversed mtDNA depletion and rescues the severe phenotype caused by *Tk2* deficiency in the mice. The deoxyribonucleotides synthesized in the cytosol are transported to mitochondria in quiescent cells. The *Dm-dNK* transgenic mouse serves as a model for deoxyribonucleoside gene or enzyme substitutions and dNTP alterations in different tissues.

The expression of *Dm-dNK* in *Tk2*<sup>-/-</sup> mice prolonged its life span of from 3 weeks to at least 20 months. The nuclear expression of *Dm-dNK* expanded dNTP pools in the cytosol and mitochondria required for mtDNA synthesis. Normal mtDNA levels were observed in skeletal muscle and liver tissues of the *Dm-dNK*<sup>+/+</sup>*Tk2*<sup>-/-</sup> mice. A large increase in the dTTP pools did not cause lethal side effects in these mice.

A mouse model with liver specific expression of the *Dm-dNK* transgene was established. Two founder mice have been characterized and will further be crossed with the *Tk2* knockout mice. This mouse model will address the questions on whether a tissue specific expression would be able to rescue the mtDNA depletion caused by *Tk2* deficiency.

The mitochondrial carrier SLC25A10 knockdown cells changed its growth properties to a less malignant phenotype. The SLC25A10 knockdown cells were more vulnerable to glutamine deprivation and lead to oxidative stress. Gene expression of genes involved in metabolic regulatory pathways and redox balance were altered in SLC25A10 knockdown cells. The metabolic alterations were linked to an energy metabolic shift from glycolysis to mitochondrial OxPhos. The SLC25A10 carrier plays an important role in regulating cancer cell redox homeostasis.

## 10 ACKNOWLEDGEMENTS

It has been an extraordinary journey, 7 years since I came to this wonderful group, and now it's all coming to an end. I have been extremely fortunate to have met some amazing people during this period without whose support none of this would have been possible. I would like to thank each and every one of you who have been a part of this journey. I wish to express my sincere gratitude to:

My supervisor, **Anna Karlsson**, you have been a great support and motivation throughout my PhD education. Thank you for accepting me in your lab and always believing in me. Thank you for all the things that you have taught me, planning experiments and doing things in an organized way, from writing a small report to writing this thesis, you have always been very encouraging and patient with me. You have been a wonderful supervisor and mentor, Thank you!

**Sophie**, thank you for being such a sweet, kind and friendly person that you are. You have been a great support throughout my PhD, always positive and so encouraging. I have turned to you for all sorts of questions, no matter how silly they were. I've admired your determination; especially trying to get me (and sometimes Xiaoshan) to go to the gym.

**Xiaoshan**, you have been a fantastic supervisor, guide and a great friend with whom I could share and discuss almost anything under the sun. Thank you for teaching me almost all of the laboratory techniques that I know today, especially for making me run all the Western blots. Thank you for all the talks about science, religion, language, people, food, marriage, and everything else.

**Marjan**, you are the 'superwoman' of the lab. Thank you for always being there for me (and everyone else). You have always been so patient even when I came with things to order just after you have done it ☺ I will cherish all our great times, the barbeques and dinners, and especially the conference in Lisbon, and our little adventure to get the flight.

**Kathrin**, you are just awesome! I came to the lab as a very and shy timid person, and the first thing you told me was 'I'm not going to eat you, so relax.' ☺ Thank you for all the cooking and baking lessons, I still haven't made it to the cupcake sessions. **Mats**, you have always been so kind and welcoming. Thank you for all the love and friendship. Looking forward to seeing you both in India soon.

**João**, you have been a really fun and cool person to work with. Thank you for all the great times in the lab and especially teaching me all about qPCR. **Qian**, although I know you only for a short while, I've really enjoyed all the discussions and chats we have had. Thank you for all the good times. **Raoul**, thank you for teaching me about how to interpret histology images, all the nice discussions and friendship.

**Simin**, where do I start? 20 kgs ‘cabbage’?, Friday breakfast shopping? do you smoke? You are fantastic! You were one of those people with whom I could really be myself. Thank you for always being there through thick and thin, for cheering me up during all the low phases, for all the amazing fun and funny times. **Babbi**, you are a sweetheart ♥. I’ve always admired the amount of energy you have and the amount of questions you ask people. Thank you for all the laughs, chats and advices about life. **Markus**, I still cannot believe that you thought I could read a book by Jan Guillou over summer to improve my Swedish ☺ Thank you for the nice friendship and all the nice discussions. **Kajsa**, my event co-organizer. Thank you for all the Fika-chats and enlightening me about western music and Christmas songs. I will definitely miss the ‘Shoobs’ call. **Raphaëlle**, you are such a warm person, thank you for all the love and the fun times. Hope we catchup in Paris soon ☺ **Halime**, my lab angel, my lab problems always get solved the moment I discussed them with you. Thank you dear for all the love and friendship. **Fredrik**, the daredevil of our lab, your pranks with dry ice (and many other things) I will never forget, thank you for the nice friendship. **Marita**, thank you for all the fun chats and discussions. You have been so supportive, both at work with all the administrative tasks, and personally. **Rekha**, thank you for being a great friend. I really appreciate all your help especially during my thesis writing. **Monica**, thank you for the nice talks and funny discussions in the lab. **Frank**, thank you for all the interesting conversations in the lab. I will always remember the mango that you bought for me on one of the Friday breakfasts. **Christina Sandström**, you were really my life savior at times ☺ Thank you for all the nice talks and friendship. **Marcel**, thank you for always hearing me out and being so supportive.

Big thanks to everyone in the Division of Microbiology and the Division of Immunology especially **Andrej, Ujjwal, Alenka, Jenny, Lidya, Lars, Neethu, Shambu, Ujjwal, Mamun, Radhika, Jezabel, Jovanka, Yin Lin, Harold, Konstantinos** and all the others for being so supportive and creating a healthy and happy environment to work.

**Sonal**, thank you for being there for me from the first day. You have been a great support throughout this journey, like a sister. Thank you for all the great great times, both at work and outside. **Sameer** bhaiya, you are such a sweet person. You have always looked out for me and made sure that I am happy. Ek cheese abhi bhi baaki hai, jo apne promise kiya tha... hope you still remember ☺ **Vidhu, Sarita** and **Rakesh** bhaiya, thank you for the wonderful friendship and all the good times.

**Sally** and **Sven-Olov**, our Swedish mother and father; thank you for your selfless and unconditional love. From the moment we landed in Sweden, you made sure we had everything and went out of your way to help us get adjusted to this new world. You both are truly amazing and I treasure each and every moment that we spent together. Mother **Maralene**, you are such a sweet and adorable person. Thank you for the innumerable fikas, the sweet discussions, and for all the love.

**Kalai** (monk, kari satti etc.) my dear dear friend. Unna pathi yezhudhanum na indha thesis pathadhu. I will cherish all the trips we've been to, the night outs and board game nights, the breakfast sessions and so many other wonderful memories forever. You were one of those who put up with all my tantrums, and have always stayed by my side no matter what. Nee oru ariya manidhan (monk) nu prove panite. Thank you for making life in Sweden sooooo much fun. **Sravs** (darlu), thank you for all the fun times. Namma eppovavdhu pesinalum, pesumbodu oru kadhai vidama pesiduvom. Thank you for being such a great friend. **Viji, Sharmi, Eddydy, Saravana** (rasavada), and **Satish** (mama), thank you all for your love and friendship. I cannot imagine how life would have been without you guys.

**Arvind** (mach), I'm soooooo thankful for your friendship. Unnoda patience ah paathu naan viyapadayaren! You have encouraged, supported me and stood by me through all times. The man with the GPS wherever we go, I will miss all the trips and fun we've had! Neeyum seekrame PhD panni 'Dr. Einstein mandayan' aaganum nu naan vendikaren ☺ **Senthil**, honey, thank you for inviting me to Kungshamra every Friday, I will cherish all the walks, talk, gossips, going to almost all the restaurants in Stockholm, the trips and especially all the science and medicine discussions! Thank you for every little thing that you have done for me. Neenga dhan enga ellarukume inspiration, vazhikaati, guru and thalaivar. **Roukn**, I will never forget your 'Inshallah'. Thank you dear Ruku for the great friendship and the great times. **Monir** and **Jan Erik**, thank you for the nice friendship and all the great times.

**Preeti** darling, and **Nari** (bhaisaab), from all the late night movies and chats in Uppsala, till the parties and fun times in here in Stockholm, every moment is so special to me. You guys have been with me through all the good and bad times and I value your friendship so much, thank you for everything. **Subbu** (vada satti) and **Swetha**, my dear satti family, you both have literally fed me and took care of me like a child throughout these years. Thank you for all the amazing, fun and crazy times together! **Sakthi** (saavi) and **Sunitha**, you both are so wonderful, so hospitable and unga kooda time spend paninadhu elame nenachu patha it was always filled with so much joy and laughter. Thank you for the wonderful friendship and all the great times. **Balaje** and **Supriya**, my gaming partners, thank you for all the amazing food, never ending board games and cards (skip balaje), and all the fun times. **Deepak, Suvarna** and **Aarush**, I cherish all the singing sessions, the get-togethers and specially my first camping experience in Utö. It has always been a pleasure spending time with you guys, thank you. **Varsha**, my 'co-entrepreneur', I always cherish that first 'girls trip' to Gotland, it was such a memorable one. Thank you for all the great times we have spent together. **Sharan, Ram, Raghu, Roshan** and **Navish**, thank you for the support and all the good times. Specially, thank you so much for being so welcoming and accommodative always. Neenga illana pala naal naan lab laye dhan thoongirpen. A big thank you from the bottom of my heart, to all the other people who have been a part of this beautiful journey.



**Sindhu** darling, my dear 52, if it weren't for you, I would never have come to Sweden. Koodiya seekram SinShu Biotec ah thodangarom! You have been one of my biggest pillars of support and I'm very thankful for having you in my life. **Viggi**, “ingu, ippozhudhu, nadandha sambavathirku, naan migavum ...” Thank you so much for everything. Even though I was so far away, our chats, our ‘over’ conversations, and the constant encouragement were very important to keep me going. Finally, idhuvum over!! Love you guys so much ♥♥♥

**Shobi**, my partner in everything. It has been sooooo wonderful to have had you so close by all these years. You have been such a great support through everything that happened during these years. Thank you dear Shobs for all the love, I love you so very much. **Kumar**, thank you for all the fun times in UK. **Ayra** kutty, my gubli, you bring so much joy and happiness to all our lives, love you so much.

**Shruuuuti** baby, my little sister, you are the most amazing sister one can have. Thank you for being there for me and constantly telling me that I can do it. I love you soooo much. My entire **family**, especially my **grandparents**, my **in-laws**, all my **cousins**, **aunts** and **uncles**, you have all been so encouraging and supportive the entire time. I am so grateful that I have such loving, wonderful people in my life. **Srivats**, thank you for being so supportive and patient. I'm looking forward to an exciting journey ahead with you.

All that I am today, I owe it to my parents. **Amma**, you let me peruse my dreams and have always backed me up even though you would have liked me to do something else, thank you. **Appa**, there is a verse that you always used to tell me when I was young: “மகன் தந்தைக்கு ஆற்றும் உதவி, ‘இவன் தந்தை என் நோற்றான் கொல்’ எனும் சொல்”. Whatever I do in my life, I keep this in mind and hope that I always make you proud. Thank you amma and appa for being the greatest parents in the world. Love you very much ♥♥♥♥♥♥

## 11 REFERENCES

1. Wallace, D.C. (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annual review of genetics*, **39**, 359-407.
2. Suomalainen, A. and Isohanni, P. (2010) Mitochondrial DNA depletion syndromes--many genes, common mechanisms. *Neuromuscul Disord*, **20**, 429-437.
3. Watson, J.D. and Crick, F.H. (1953) Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. *Nature*, **171**, 737-738.
4. Elledge, S.J. (1996) Cell cycle checkpoints: preventing an identity crisis. *Science*, **274**, 1664-1672.
5. Ropp, P.A. and Copeland, W.C. (1996) Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. *Genomics*, **36**, 449-458.
6. Tyynismaa, H., Sembongi, H., Bokori-Brown, M., Granycome, C., Ashley, N., Poulton, J., Jalanko, A., Spelbrink, J.N., Holt, I.J. and Suomalainen, A. (2004) Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number. *Hum Mol Genet*, **13**, 3219-3227.
7. Bogenhagen, D. and Clayton, D.A. (1977) Mouse L cell mitochondrial DNA molecules are selected randomly for replication throughout the cell cycle. *Cell*, **11**, 719-727.
8. Magnusson, J., Orth, M., Lestienne, P. and Taanman, J.W. (2003) Replication of mitochondrial DNA occurs throughout the mitochondria of cultured human cells. *Experimental cell research*, **289**, 133-142.
9. Van Rompay, A.R., Johansson, M. and Karlsson, A. (2000) Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. *Pharmacology & therapeutics*, **87**, 189-198.
10. Panayiotou, C., Solaroli, N. and Karlsson, A. (2014) The many isoforms of human adenylate kinases. *The international journal of biochemistry & cell biology*, **49**, 75-83.
11. Thelander, L. and Reichard, P. (1979) Reduction of ribonucleotides. *Annu Rev Biochem*, **48**, 133-158.
12. de la Rosa, A., Williams, R.L. and Steeg, P.S. (1995) Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. *BioEssays : news and reviews in molecular, cellular and developmental biology*, **17**, 53-62.
13. Lacombe, M.L., Milon, L., Munier, A., Mehus, J.G. and Lambeth, D.O. (2000) The human Nm23/nucleoside diphosphate kinases. *J Bioenerg Biomembr*, **32**, 247-258.
14. Francois-Moutal, L., Marcillat, O. and Granjon, T. (2014) Structural comparison of highly similar nucleoside-diphosphate kinases: Molecular explanation of distinct membrane-binding behavior. *Biochimie*, **105**, 110-118.
15. Arner, E.S. and Eriksson, S. (1995) Mammalian deoxyribonucleoside kinases. *Pharmacology & therapeutics*, **67**, 155-186.
16. Van Rompay, A.R., Johansson, M. and Karlsson, A. (2003) Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. *Pharmacology & therapeutics*, **100**, 119-139.
17. Brown, N.C. and Reichard, P. (1969) Ribonucleoside diphosphate reductase. Formation of active and inactive complexes of proteins B1 and B2. *Journal of molecular biology*, **46**, 25-38.
18. Eriksson, S., Graslund, A., Skog, S., Thelander, L. and Tribukait, B. (1984) Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. *The Journal of biological chemistry*, **259**, 11695-11700.
19. Reichard, P. (1988) Interactions between Deoxyribonucleotide and DNA-Synthesis. *Annu Rev Biochem*, **57**, 349-374.
20. Engstrom, Y., Eriksson, S., Jildevik, I., Skog, S., Thelander, L. and Tribukait, B. (1985) Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. *The Journal of biological chemistry*, **260**, 9114-9116.
21. Mann, G.J., Musgrove, E.A., Fox, R.M. and Thelander, L. (1988) Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. *Cancer research*, **48**, 5151-5156.

22. Arner, E.S., Spasokoukotskaja, T. and Eriksson, S. (1992) Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. *Biochemical and biophysical research communications*, **188**, 712-718.
23. Wang, L., Karlsson, A., Arner, E.S. and Eriksson, S. (1993) Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. *The Journal of biological chemistry*, **268**, 22847-22852.
24. Johansson, M. and Karlsson, A. (1996) Cloning and expression of human deoxyguanosine kinase cDNA. *P Natl Acad Sci USA*, **93**, 7258-7262.
25. Johansson, M. and Karlsson, A. (1997) Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2. *The Journal of biological chemistry*, **272**, 8454-8458.
26. Sjoberg, A.H., Wang, L. and Eriksson, S. (1998) Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. *Molecular pharmacology*, **53**, 270-273.
27. Wang, L. and Eriksson, S. (2000) Cloning and characterization of full-length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. *The Biochemical journal*, **351 Pt 2**, 469-476.
28. Bjorklund, S., Skog, S., Tribukait, B. and Thelander, L. (1990) S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. *Biochemistry*, **29**, 5452-5458.
29. Munch-Petersen, B., Cloos, L., Jensen, H.K. and Tyrsted, G. (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. *Advances in enzyme regulation*, **35**, 69-89.
30. Chabes, A. and Thelander, L. (2000) Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. *The Journal of biological chemistry*, **275**, 17747-17753.
31. Johansson, M. and Karlsson, A. (1995) Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase. *Biochem Pharmacol*, **50**, 163-168.
32. Greenblatt, M.S., Bennett, W.P., Hollstein, M. and Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer research*, **54**, 4855-4878.
33. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. *Cell*, **88**, 323-331.
34. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y. and Nakamura, Y. (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature*, **404**, 42-49.
35. Guittet, O., Hakansson, P., Voevodskaya, N., Fridd, S., Graslund, A., Arakawa, H., Nakamura, Y. and Thelander, L. (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. *The Journal of biological chemistry*, **276**, 40647-40651.
36. Hakansson, P., Hofer, A. and Thelander, L. (2006) Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. *The Journal of biological chemistry*, **281**, 7834-7841.
37. Pontarin, G., Ferraro, P., Hakansson, P., Thelander, L., Reichard, P. and Bianchi, V. (2007) p53R2-dependent ribonucleotide reduction provides Deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage. *Journal of Biological Chemistry*, **282**, 16820-16828.
38. Pontarin, G., Ferraro, P., Bee, L., Reichard, P. and Bianchi, V. (2012) Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. *P Natl Acad Sci USA*, **109**, 13302-13307.
39. Kunz, B.A., Kohalmi, S.E., Kunkel, T.A., Mathews, C.K., McIntosh, E.M. and Reidy, J.A. (1994) International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. *Mutation research*, **318**, 1-64.
40. Mathews, C.K. (2006) DNA precursor metabolism and genomic stability. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, **20**, 1300-1314.

41. Kumar, D., Viberg, J., Nilsson, A.K. and Chabes, A. (2010) Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. *Nucleic Acids Res*, **38**, 3975-3983.
42. Kumar, D., Abdulovic, A.L., Viberg, J., Nilsson, A.K., Kunkel, T.A. and Chabes, A. (2011) Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. *Nucleic Acids Res*, **39**, 1360-1371.
43. Rampazzo, C., Miazzi, C., Franzolin, E., Pontarin, G., Ferraro, P., Frangini, M., Reichard, P. and Bianchi, V. (2010) Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. *Mutation research*, **703**, 2-10.
44. Eriksson, S., Munch-Petersen, B., Johansson, K. and Eklund, H. (2002) Structure and function of cellular deoxyribonucleoside kinases. *Cellular and molecular life sciences : CMLS*, **59**, 1327-1346.
45. Gandhi, V.V. and Samuels, D.C. (2011) A review comparing deoxyribonucleoside triphosphate (dNTP) concentrations in the mitochondrial and cytoplasmic compartments of normal and transformed cells. *Nucleosides, nucleotides & nucleic acids*, **30**, 317-339.
46. Bestwick, R.K., Moffett, G.L. and Mathews, C.K. (1982) Selective expansion of mitochondrial nucleoside triphosphate pools in antimetabolite-treated HeLa cells. *The Journal of biological chemistry*, **257**, 9300-9304.
47. Bestwick, R.K. and Mathews, C.K. (1982) Unusual compartmentation of precursors for nuclear and mitochondrial DNA in mouse L cells. *The Journal of biological chemistry*, **257**, 9305-9308.
48. Bridges, E.G., Jiang, Z. and Cheng, Y.C. (1999) Characterization of a dCTP transport activity reconstituted from human mitochondria. *The Journal of biological chemistry*, **274**, 4620-4625.
49. Pontarin, G., Gallinaro, L., Ferraro, P., Reichard, P. and Bianchi, V. (2003) Origins of mitochondrial thymidine triphosphate: dynamic relations to cytosolic pools. *P Natl Acad Sci USA*, **100**, 12159-12164.
50. Rampazzo, C., Ferraro, P., Pontarin, G., Fabris, S., Reichard, P. and Bianchi, V. (2004) Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation. *The Journal of biological chemistry*, **279**, 17019-17026.
51. Lee, E.W., Lai, Y., Zhang, H. and Unadkat, J.D. (2006) Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. *The Journal of biological chemistry*, **281**, 16700-16706.
52. Lai, Y., Tse, C.M. and Unadkat, J.D. (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. *The Journal of biological chemistry*, **279**, 4490-4497.
53. Franzolin, E., Miazzi, C., Frangini, M., Palumbo, E., Rampazzo, C. and Bianchi, V. (2012) The pyrimidine nucleotide carrier PNC1 and mitochondrial trafficking of thymidine phosphates in cultured human cells. *Experimental cell research*, **318**, 2226-2236.
54. Di Noia, M.A., Todisco, S., Cirigliano, A., Rinaldi, T., Agrimi, G., Iacobazzi, V. and Palmieri, F. (2014) The human SLC25A33 and SLC25A36 genes of solute carrier family 25 encode two mitochondrial pyrimidine nucleotide transporters. *The Journal of biological chemistry*, **289**, 33137-33148.
55. Copeland, W.C. (2012) Defects in mitochondrial DNA replication and human disease. *Crit Rev Biochem Mol*, **47**, 64-74.
56. Mathews, C.K. (2015) Deoxyribonucleotide metabolism, mutagenesis and cancer. *Nature reviews. Cancer*, **15**, 528-539.
57. Adams, M.D., Celniker, S.E., Holt, R.A., Evans, C.A., Gocayne, J.D., Amanatides, P.G., Scherer, S.E., Li, P.W., Hoskins, R.A., Galle, R.F. *et al.* (2000) The genome sequence of *Drosophila melanogaster*. *Science*, **287**, 2185-2195.
58. Rubin, G.M., Yandell, M.D., Wortman, J.R., Gabor Miklos, G.L., Nelson, C.R., Hariharan, I.K., Fortini, M.E., Li, P.W., Apweiler, R., Fleischmann, W. *et al.* (2000) Comparative genomics of the eukaryotes. *Science*, **287**, 2204-2215.
59. Lewis, D.L., Farr, C.L. and Kaguni, L.S. (1995) *Drosophila melanogaster* mitochondrial DNA: completion of the nucleotide sequence and evolutionary comparisons. *Insect molecular biology*, **4**, 263-278.

60. Peck, V.M., Gerner, E.W. and Cress, A.E. (1992) Delta-type DNA polymerase characterized from *Drosophila melanogaster* embryos. *Nucleic Acids Res*, **20**, 5779-5784.
61. Bakkenist, C.J. and Cotterill, S. (1994) The 50-kDa primase subunit of *Drosophila melanogaster* DNA polymerase alpha. Molecular characterization of the gene and functional analysis of the overexpressed protein. *The Journal of biological chemistry*, **269**, 26759-26766.
62. Lewis, D.L., Farr, C.L., Wang, Y., Lagina, A.T., 3rd and Kaguni, L.S. (1996) Catalytic subunit of mitochondrial DNA polymerase from *Drosophila* embryos. Cloning, bacterial overexpression, and biochemical characterization. *The Journal of biological chemistry*, **271**, 23389-23394.
63. Aoyagi, N., Oshige, M., Hirose, F., Kuroda, K., Matsukage, A. and Sakaguchi, K. (1997) DNA polymerase epsilon from *Drosophila melanogaster*. *Biochemical and biophysical research communications*, **230**, 297-301.
64. Munch-Petersen, B., Piskur, J. and Sondergaard, L. (1998) The single deoxynucleoside kinase in *Drosophila melanogaster*, Dm-dNK, is multifunctional and differs from the mammalian deoxynucleoside kinases. *Advances in experimental medicine and biology*, **431**, 465-469.
65. Munch-Petersen, B., Piskur, J. and Sondergaard, L. (1998) Four deoxynucleoside kinase activities from *Drosophila melanogaster* are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase. *The Journal of biological chemistry*, **273**, 3926-3931.
66. Johansson, M., van Rompay, A.R., Degreve, B., Balzarini, J. and Karlsson, A. (1999) Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of *Drosophila melanogaster*. *The Journal of biological chemistry*, **274**, 23814-23819.
67. Munch-Petersen, B., Knecht, W., Lenz, C., Sondergaard, L. and Piskur, J. (2000) Functional expression of a multisubstrate deoxyribonucleoside kinase from *Drosophila melanogaster* and its C-terminal deletion mutants. *The Journal of biological chemistry*, **275**, 6673-6679.
68. Knecht, W., Munch-Petersen, B. and Piskur, J. (2000) Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from *Drosophila melanogaster*. *Journal of molecular biology*, **301**, 827-837.
69. Mouse Genome Sequencing, C., Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, P., Agarwala, R., Ainscough, R., Alexandersson, M. *et al.* (2002) Initial sequencing and comparative analysis of the mouse genome. *Nature*, **420**, 520-562.
70. Bibb, M.J., Van Etten, R.A., Wright, C.T., Walberg, M.W. and Clayton, D.A. (1981) Sequence and gene organization of mouse mitochondrial DNA. *Cell*, **26**, 167-180.
71. Hall, B., Limaye, A. and Kulkarni, A.B. (2009) Overview: generation of gene knockout mice. *Current protocols in cell biology*, **Chapter 19**, Unit 19 12 19 12 11-17.
72. Doyle, A., McGarry, M.P., Lee, N.A. and Lee, J.J. (2012) The construction of transgenic and gene knockout/knockin mouse models of human disease. *Transgenic research*, **21**, 327-349.
73. Gray, M.W. (2012) Mitochondrial evolution. *Cold Spring Harbor perspectives in biology*, **4**, a011403.
74. Duchen, M.R. (2000) Mitochondria and calcium: from cell signalling to cell death. *The Journal of physiology*, **529 Pt 1**, 57-68.
75. Wang, C. and Youle, R.J. (2009) The role of mitochondria in apoptosis\*. *Annual review of genetics*, **43**, 95-118.
76. Tait, S.W. and Green, D.R. (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. *Nature reviews. Molecular cell biology*, **11**, 621-632.
77. Lill, R., Hoffmann, B., Molik, S., Pierik, A.J., Rietzschel, N., Stehling, O., Uzarska, M.A., Webert, H., Wilbrecht, C. and Muhlenhoff, U. (2012) The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. *Biochimica et biophysica acta*, **1823**, 1491-1508.
78. Rizzuto, R., De Stefani, D., Raffaello, A. and Mammucari, C. (2012) Mitochondria as sensors and regulators of calcium signalling. *Nature reviews. Molecular cell biology*, **13**, 566-578.
79. Cloonan, S.M. and Choi, A.M. (2013) Mitochondria: sensors and mediators of innate immune receptor signaling. *Current opinion in microbiology*, **16**, 327-338.
80. Stehling, O. and Lill, R. (2013) The role of mitochondria in cellular iron-sulfur protein biogenesis: mechanisms, connected processes, and diseases. *Cold Spring Harbor perspectives in biology*, **5**, a011312.

81. Bratic, A. and Larsson, N.G. (2013) The role of mitochondria in aging. *The Journal of clinical investigation*, **123**, 951-957.
82. Weinberg, S.E., Sena, L.A. and Chandel, N.S. (2015) Mitochondria in the regulation of innate and adaptive immunity. *Immunity*, **42**, 406-417.
83. Anderson, S., Bankier, A.T., Barrell, B.G., de Bruijn, M.H., Coulson, A.R., Drouin, J., Eperon, I.C., Nierlich, D.P., Roe, B.A., Sanger, F. *et al.* (1981) Sequence and organization of the human mitochondrial genome. *Nature*, **290**, 457-465.
84. Dimauro, S. (2004) Mitochondrial medicine. *Biochimica et biophysica acta*, **1659**, 107-114.
85. Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, G.A., Sugiana, C., Boneh, A., Chen, W.K. *et al.* (2008) A mitochondrial protein compendium elucidates complex I disease biology. *Cell*, **134**, 112-123.
86. Schmidt, O., Pfanner, N. and Meisinger, C. (2010) Mitochondrial protein import: from proteomics to functional mechanisms. *Nature reviews. Molecular cell biology*, **11**, 655-667.
87. Ingman, M., Kaessmann, H., Paabo, S. and Gyllensten, U. (2000) Mitochondrial genome variation and the origin of modern humans. *Nature*, **408**, 708-713.
88. Holt, I.J. and Reyes, A. (2012) Human mitochondrial DNA replication. *Cold Spring Harbor perspectives in biology*, **4**.
89. Taanman, J.W., Bodnar, A.G., Cooper, J.M., Morris, A.A., Clayton, P.T., Leonard, J.V. and Schapira, A.H. (1997) Molecular mechanisms in mitochondrial DNA depletion syndrome. *Hum Mol Genet*, **6**, 935-942.
90. Moraes, C.T., Shanske, S., Tritchler, H.J., Aprille, J.R., Andretta, F., Bonilla, E., Schon, E.A. and DiMauro, S. (1991) mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. *American journal of human genetics*, **48**, 492-501.
91. Suomalainen, A. and Kaukonen, J. (2001) Diseases caused by nuclear genes affecting mtDNA stability. *American journal of medical genetics*, **106**, 53-61.
92. Spinazzola, A., Invernizzi, F., Carrara, F., Lamantea, E., Donati, A., Dirocco, M., Giordano, I., Meznaric-Petrusa, M., Baruffini, E., Ferrero, I. *et al.* (2009) Clinical and molecular features of mitochondrial DNA depletion syndromes. *Journal of inherited metabolic disease*, **32**, 143-158.
93. Huang, C.C. and Hsu, C.H. (2009) [Mitochondrial disease and mitochondrial DNA depletion syndromes]. *Acta neurologica Taiwanica*, **18**, 287-295.
94. Saada, A., Shaag, A., Mandel, H., Nevo, Y., Eriksson, S. and Elpeleg, O. (2001) Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. *Nat Genet*, **29**, 342-344.
95. Mancuso, M., Salviati, L., Sacconi, S., Otaegui, D., Camano, P., Marina, A., Bacman, S., Moraes, C.T., Carlo, J.R., Garcia, M. *et al.* (2002) Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. *Neurology*, **59**, 1197-1202.
96. Mancuso, M., Filosto, M., Bonilla, E., Hirano, M., Shanske, S., Vu, T.H. and DiMauro, S. (2003) Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a homozygous mutation (T77M) in the TK2 gene. *Archives of neurology*, **60**, 1007-1009.
97. Oskoui, M., Davidzon, G., Pascual, J., Erazo, R., Gurgel-Giannetti, J., Krishna, S., Bonilla, E., De Vivo, D.C., Shanske, S. and DiMauro, S. (2006) Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. *Archives of neurology*, **63**, 1122-1126.
98. Chanprasert, S., Wang, J., Weng, S.W., Enns, G.M., Boue, D.R., Wong, B.L., Mendell, J.R., Perry, D.A., Sahenk, Z., Craigen, W.J. *et al.* (2013) Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene. *Molecular genetics and metabolism*, **110**, 153-161.
99. Tynismaa, H., Sun, R., Ahola-Erkila, S., Almusa, H., Poyhonen, R., Korpela, M., Honkaniemi, J., Isohanni, P., Paetau, A., Wang, L. *et al.* (2012) Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. *Hum Mol Genet*, **21**, 66-75.
100. Behin, A., Jardel, C., Claeys, K.G., Fagart, J., Louha, M., Romero, N.B., Laforet, P., Eymard, B. and Lombes, A. (2012) Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum. *Neurology*, **78**, 644-648.

101. Gotz, A., Isohanni, P., Pihko, H., Paetau, A., Herva, R., Saarenpaa-Heikkila, O., Valanne, L., Marjavaara, S. and Suomalainen, A. (2008) Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. *Brain*, **131**, 2841-2850.
102. Lesko, N., Naess, K., Wibom, R., Solaroli, N., Nennesmo, I., von Döbeln, U., Karlsson, A. and Larsson, N.G. (2010) Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion. *Neuromuscul Disord*, **20**, 198-203.
103. El-Hattab, A.W. and Scaglia, F. (2013) Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, **10**, 186-198.
104. Chanprasert S, Wong LJC, Wang J, et al. TK2-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form. 2012 Dec 6. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK114628/>
105. Mandel, H., Szargel, R., Labay, V., Elpeleg, O., Saada, A., Shalata, A., Anbinder, Y., Berkowitz, D., Hartman, C., Barak, M. *et al.* (2001) The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. *Nat Genet*, **29**, 491-491.
106. Salvati, L., Sacconi, S., Mancuso, M., Otaegui, D., Camano, P., Marina, A., Rabinowitz, S., Shiffman, R., Thompson, K., Wilson, C.M. *et al.* (2002) Mitochondrial DNA depletion and dGK gene mutations. *Annals of neurology*, **52**, 311-317.
107. Taanman, J.W., Kateeb, I., Muntau, A.C., Jaksch, M., Cohen, N. and Mandel, H. (2002) A novel mutation in the deoxyguanosine kinase gene causing depletion of mitochondrial DNA. *Annals of neurology*, **52**, 237-239.
108. Wang, L., Limongelli, A., Vila, M.R., Carrara, F., Zeviani, M. and Eriksson, S. (2005) Molecular insight into mitochondrial DNA depletion syndrome in two patients with novel mutations in the deoxyguanosine kinase and thymidine kinase 2 genes. *Molecular genetics and metabolism*, **84**, 75-82.
109. Labarthe, F., Dobbelaere, D., Devisme, L., De Muret, A., Jardel, C., Taanman, J.W., Gottrand, F. and Lombes, A. (2005) Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. *Journal of hepatology*, **43**, 333-341.
110. Dimmock, D.P., Zhang, Q., Dionisi-Vici, C., Carrozzo, R., Shieh, J., Tang, L.Y., Truong, C., Schmitt, E., Sifry-Platt, M., Luciola, S. *et al.* (2008) Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. *Human mutation*, **29**, 330-331.
111. Scaglia F, Dimmock D, Wong LJ. DGUOK-Related Mitochondrial DNA Depletion Syndrome, Hepatocerebral Form. 2009 Jun 18. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK7040/>
112. Rylova, S.N., Albertioni, F., Flygh, G. and Eriksson, S. (2005) Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. *Biochem Pharmacol*, **69**, 951-960.
113. Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W. and Heldin, C.H. (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature*, **338**, 557-562.
114. Matsukawa, K., Moriyama, A., Kawai, Y., Asai, K. and Kato, T. (1996) Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression. *Biochimica et biophysica acta*, **1314**, 71-82.
115. Griffiths, L. and Stratford, I.J. (1997) Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. *British journal of cancer*, **76**, 689-693.
116. Nishino, I., Spinazzola, A. and Hirano, M. (1999) Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. *Science*, **283**, 689-692.
117. Hirano, M., Marti, R., Spinazzola, A., Nishino, I. and Nishigaki, Y. (2004) Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder. *Nucleosides, nucleotides & nucleic acids*, **23**, 1217-1225.

118. Taanman, J.W., Daras, M., Albrecht, J., Davie, C.A., Mallam, E.A., Muddle, J.R., Weatherall, M., Warner, T.T., Schapira, A.H. and Ginsberg, L. (2009) Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). *Neuromuscul Disord*, **19**, 151-154.
119. Spinazzola, A., Marti, R., Nishino, I., Andreu, A.L., Naini, A., Tadesse, S., Pela, I., Zammarchi, E., Donati, M.A., Oliver, J.A. *et al.* (2002) Altered thymidine metabolism due to defects of thymidine phosphorylase. *The Journal of biological chemistry*, **277**, 4128-4133.
120. Nordlund, P. and Reichard, P. (2006) Ribonucleotide reductases. *Annu Rev Biochem*, **75**, 681-706.
121. Yamaguchi, T., Matsuda, K., Sagiya, Y., Iwadate, M., Fujino, M.A., Nakamura, Y. and Arakawa, H. (2001) p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. *Cancer research*, **61**, 8256-8262.
122. Bourdon, A., Minai, L., Serre, V., Jais, J.P., Sarzi, E., Aubert, S., Chretien, D., de Lonlay, P., Paquis-Flucklinger, V., Arakawa, H. *et al.* (2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. *Nat Genet*, **39**, 776-780.
123. Bornstein, B., Area, E., Flanigan, K.M., Ganesh, J., Jayakar, P., Swoboda, K.J., Coku, J., Naini, A., Shanske, S., Tanji, K. *et al.* (2008) Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. *Neuromuscul Disord*, **18**, 453-459.
124. Kollberg, G., Darin, N., Benan, K., Moslemi, A.R., Lindal, S., Tulinius, M., Oldfors, A. and Holme, E. (2009) A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. *Neuromuscul Disord*, **19**, 147-150.
125. Shaibani, A., Shchelochkov, O.A., Zhang, S., Katsonis, P., Lichtarge, O., Wong, L.J. and Shinawi, M. (2009) Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. *Archives of neurology*, **66**, 1028-1032.
126. Johnson, J.D., Mehus, J.G., Tews, K., Milavetz, B.I. and Lambeth, D.O. (1998) Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes. *The Journal of biological chemistry*, **273**, 27580-27586.
127. Ostergaard, E. (2008) Disorders caused by deficiency of succinate-CoA ligase. *Journal of inherited metabolic disease*, **31**, 226-229.
128. Miller, C., Wang, L., Ostergaard, E., Dan, P. and Saada, A. (2011) The interplay between SUCLA2, SUCLG2, and mitochondrial DNA depletion. *Biochimica et biophysica acta*, **1812**, 625-629.
129. Carozzo, R., Verrigni, D., Rasmussen, M., de Coo, R., Amartino, H., Bianchi, M., Buhas, D., Mesli, S., Naess, K., Born, A.P. *et al.* (2016) Succinate-CoA ligase deficiency due to mutations in SUCLA2 and SUCLG1: phenotype and genotype correlations in 71 patients. *Journal of inherited metabolic disease*, **39**, 243-252.
130. Lambeth, D.O., Tews, K.N., Adkins, S., Frohlich, D. and Milavetz, B.I. (2004) Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues. *The Journal of biological chemistry*, **279**, 36621-36624.
131. Van Hove, J.L., Saenz, M.S., Thomas, J.A., Gallagher, R.C., Lovell, M.A., Fenton, L.Z., Shanske, S., Myers, S.M., Wanders, R.J., Ruiter, J. *et al.* (2010) Succinyl-CoA ligase deficiency: a mitochondrial hepatoencephalomyopathy. *Pediatric research*, **68**, 159-164.
132. Dobolyi, A., Ostergaard, E., Bago, A.G., Doczi, T., Palkovits, M., Gal, A., Molnar, M.J., Adam-Vizi, V. and Chinopoulos, C. (2015) Exclusive neuronal expression of SUCLA2 in the human brain. *Brain structure & function*, **220**, 135-151.
133. Elpeleg, O., Miller, C., Hershkovitz, E., Bitner-Glindzicz, M., Bondi-Rubinstein, G., Rahman, S., Pagnamenta, A., Eshhar, S. and Saada, A. (2005) Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. *American journal of human genetics*, **76**, 1081-1086.
134. Ostergaard, E., Hansen, F.J., Sorensen, N., Duno, M., Vissing, J., Larsen, P.L., Faeroe, O., Thorgrimsson, S., Wibrand, F., Christensen, E. *et al.* (2007) Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. *Brain*, **130**, 853-861.
135. Carozzo, R., Dionisi-Vici, C., Steuerwald, U., Lucioli, S., Deodato, F., Di Giandomenico, S., Bertini, E., Franke, B., Kluijtmans, L.A., Meschini, M.C. *et al.* (2007) SUCLA2 mutations are



- associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. *Brain*, **130**, 862-874.
136. Morava, E., Steuerwald, U., Carozzo, R., Kluijtmans, L.A., Joensen, F., Santer, R., Dionisi-Vici, C. and Wevers, R.A. (2009) Dystonia and deafness due to SUCLA2 defect; Clinical course and biochemical markers in 16 children. *Mitochondrion*, **9**, 438-442.
  137. Ostergaard, E., Schwartz, M., Batbayli, M., Christensen, E., Hjalmarson, O., Kollberg, G. and Holme, E. (2010) A novel missense mutation in SUCLG1 associated with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria. *European journal of pediatrics*, **169**, 201-205.
  138. Ostergaard, E., Christensen, E., Kristensen, E., Mogensen, B., Duno, M., Shoubridge, E.A. and Wibrand, F. (2007) Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. *American journal of human genetics*, **81**, 383-387.
  139. Rouzier, C., Le Guedard-Mereuze, S., Fragaki, K., Serre, V., Miro, J., Tuffery-Giraud, S., Chaussonot, A., Bannwarth, S., Caruba, C., Ostergaard, E. *et al.* (2010) The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein. *Journal of medical genetics*, **47**, 670-676.
  140. Lestienne, P. (1987) Evidence for a direct role of the DNA polymerase gamma in the replication of the human mitochondrial DNA in vitro. *Biochemical and biophysical research communications*, **146**, 1146-1153.
  141. Lecrenier, N., Van Der Bruggen, P. and Foury, F. (1997) Mitochondrial DNA polymerases from yeast to man: a new family of polymerases. *Gene*, **185**, 147-152.
  142. Lim, S.E., Longley, M.J. and Copeland, W.C. (1999) The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. *The Journal of biological chemistry*, **274**, 38197-38203.
  143. Graziewicz, M.A., Longley, M.J. and Copeland, W.C. (2006) DNA polymerase gamma in mitochondrial DNA replication and repair. *Chemical reviews*, **106**, 383-405.
  144. Kasiviswanathan, R., Gustafson, M.A., Copeland, W.C. and Meyer, J.N. (2012) Human mitochondrial DNA polymerase gamma exhibits potential for bypass and mutagenesis at UV-induced cyclobutane thymine dimers. *The Journal of biological chemistry*, **287**, 9222-9229.
  145. Cohen, B.H. and Naviaux, R.K. (2010) The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. *Methods*, **51**, 364-373.
  146. Milone, M. and Massie, R. (2010) Polymerase gamma 1 mutations: clinical correlations. *The neurologist*, **16**, 84-91.
  147. Stumpf, J.D. and Copeland, W.C. (2011) Mitochondrial DNA replication and disease: insights from DNA polymerase gamma mutations. *Cellular and molecular life sciences : CMLS*, **68**, 219-233.
  148. Spelbrink, J.N., Li, F.Y., Tiranti, V., Nikali, K., Yuan, Q.P., Tariq, M., Wanrooij, S., Garrido, N., Comi, G., Morandi, L. *et al.* (2001) Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. *Nat Genet*, **28**, 223-231.
  149. Nikali, K., Suomalainen, A., Saharinen, J., Kuokkanen, M., Spelbrink, J.N., Lonnqvist, T. and Peltonen, L. (2005) Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. *Hum Mol Genet*, **14**, 2981-2990.
  150. Lewis, S., Hutchison, W., Thyagarajan, D. and Dahl, H.H.M. (2002) Clinical and molecular features of adPEO due to mutations in the Twinkle gene. *Journal of the neurological sciences*, **201**, 39-44.
  151. Echaniz-Laguna, A., Chanson, J.B., Wilhelm, J.M., Sellal, F., Mayencon, M., Mohr, M., Tranchant, C. and Mousson de Camaret, B. (2010) A novel variation in the Twinkle linker region causing late-onset dementia. *Neurogenetics*, **11**, 21-25.
  152. Hakonen, A.H., Goffart, S., Marjavaara, S., Paetau, A., Cooper, H., Mattila, K., Lampinen, M., Sajantila, A., Lonnqvist, T., Spelbrink, J.N. *et al.* (2008) Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. *Hum Mol Genet*, **17**, 3822-3835.

153. Sarzi, E., Goffart, S., Serre, V., Chretien, D., Slama, A., Munnich, A., Spelbrink, J.N. and Rotig, A. (2007) Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. *Annals of neurology*, **62**, 579-587.
154. Spinazzola, A., Viscomi, C., Fernandez-Vizarra, E., Carrara, F., D'Adamo, P., Calvo, S., Marsano, R.M., Donnini, C., Weiher, H., Strisciuglio, P. *et al.* (2006) MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. *Nat Genet*, **38**, 570-575.
155. Uusimaa, J., Evans, J., Smith, C., Butterworth, A., Craig, K., Ashley, N., Liao, C., Carver, J., Diot, A., Macleod, L. *et al.* (2014) Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. *European journal of human genetics : EJHG*, **22**, 184-191.
156. Singleton, R., Helgeson, S.D., Snyder, R.D., O'Conner, P.J., Nelson, S., Johnsen, S.D. and Allanson, J.E. (1990) Neuropathy in Navajo children: clinical and epidemiologic features. *Neurology*, **40**, 363-367.
157. Holve, S., Hu, D., Shub, M., Tyson, R.W. and Sokol, R.J. (1999) Liver disease in Navajo neuropathy. *The Journal of pediatrics*, **135**, 482-493.
158. Spinazzola, A., Santer, R., Akman, O.H., Tsiakas, K., Schaefer, H., Ding, X., Karadimas, C.L., Shanske, S., Ganesh, J., Di Mauro, S. *et al.* (2008) Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. *Archives of neurology*, **65**, 1108-1113.
159. El-Hattab, A.W., Li, F.Y., Schmitt, E., Zhang, S., Craigen, W.J. and Wong, L.J. (2010) MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations. *Molecular genetics and metabolism*, **99**, 300-308.
160. Calvo, S.E., Compton, A.G., Hershman, S.G., Lim, S.C., Lieber, D.S., Tucker, E.J., Laskowski, A., Garone, C., Liu, S., Jaffe, D.B. *et al.* (2012) Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. *Science translational medicine*, **4**, 118ra110.
161. Kornblum, C., Nicholls, T.J., Haack, T.B., Scholer, S., Peeva, V., Danhauser, K., Hallmann, K., Zsurka, G., Rorbach, J., Iuso, A. *et al.* (2013) Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. *Nat Genet*, **45**, 214-219.
162. Gai, X., Ghezzi, D., Johnson, M.A., Biagosch, C.A., Shamseldin, H.E., Haack, T.B., Reyes, A., Tsukikawa, M., Sheldon, C.A., Srinivasan, S. *et al.* (2013) Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. *American journal of human genetics*, **93**, 482-495.
163. Bonnen, P.E., Yarham, J.W., Besse, A., Wu, P., Faqeih, E.A., Al-Asmari, A.M., Saleh, M.A., Eyaid, W., Hadeel, A., He, L. *et al.* (2013) Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. *American journal of human genetics*, **93**, 471-481.
164. Baroy, T., Pedurupillay, C.R., Blikrud, Y.T., Rasmussen, M., Holmgren, A., Vigeland, M.D., Hughes, T., Brink, M., Rodenburg, R., Nedregaard, B. *et al.* (2016) A novel mutation in FBXL4 in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13. *European journal of medical genetics*, **59**, 342-346.
165. Spiegel, R., Saada, A., Flannery, P.J., Burte, F., Soiferman, D., Khayat, M., Eisner, V., Vladovski, E., Taylor, R.W., Bindoff, L.A. *et al.* (2016) Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation. *Journal of medical genetics*, **53**, 127-131.
166. Stiles, A.R., Simon, M.T., Stover, A., Eftekharian, S., Khanlou, N., Wang, H.L., Magaki, S., Lee, H., Partynski, K., Dorrani, N. *et al.* (2016) Mutations in TFAM, encoding mitochondrial transcription factor A, cause neonatal liver failure associated with mtDNA depletion. *Molecular genetics and metabolism*, **119**, 91-99.
167. Akman, H.O., Dorado, B., Lopez, L.C., Garcia-Cazorla, A., Vila, M.R., Tanabe, L.M., Dauer, W.T., Bonilla, E., Tanji, K. and Hirano, M. (2008) Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. *Hum Mol Genet*, **17**, 2433-2440.

168. Zhou, X., Solaroli, N., Bjerke, M., Stewart, J.B., Rozell, B., Johansson, M. and Karlsson, A. (2008) Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. *Hum Mol Genet*, **17**, 2329-2335.
169. Bartesaghi, S., Betts-Henderson, J., Cain, K., Dinsdale, D., Zhou, X., Karlsson, A., Salomoni, P. and Nicotera, P. (2010) Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. *Hum Mol Genet*, **19**, 1669-1677.
170. Villarroya, J., Dorado, B., Vila, M.R., Garcia-Arumi, E., Domingo, P., Giralt, M., Hirano, M. and Villarroya, F. (2011) Thymidine kinase 2 deficiency-induced mitochondrial DNA depletion causes abnormal development of adipose tissues and adipokine levels in mice. *PLoS one*, **6**, e29691.
171. Dorado, B., Area, E., Akman, H.O. and Hirano, M. (2011) Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensation. *Hum Mol Genet*, **20**, 155-164.
172. Zhou, X., Kannisto, K., Curbo, S., von Döbeln, U., Hultén, K., Isetun, S., Gafvels, M. and Karlsson, A. (2013) Thymidine kinase 2 deficiency-induced mtDNA depletion in mouse liver leads to defect beta-oxidation. *PLoS one*, **8**, e58843.
173. Bennett, B., Helbling, D., Meng, H., Jarzembowski, J., Geurts, A.M., Friederich, M.W., Van Hove, J.L., Lawlor, M.W. and Dimmock, D.P. (2016) Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome. *Free radical biology & medicine*, **92**, 141-151.
174. Haraguchi, M., Tsujimoto, H., Fukushima, M., Higuchi, I., Kuribayashi, H., Utsumi, H., Nakayama, A., Hashizume, Y., Hirato, J., Yoshida, H. *et al.* (2002) Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. *Mol Cell Biol*, **22**, 5212-5221.
175. Lopez, L.C., Akman, H.O., Garcia-Cazorla, A., Dorado, B., Marti, R., Nishino, I., Tadesse, S., Pizzorno, G., Shungu, D., Bonilla, E. *et al.* (2009) Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. *Hum Mol Genet*, **18**, 714-722.
176. Garcia-Diaz, B., Garone, C., Barca, E., Mojahed, H., Gutierrez, P., Pizzorno, G., Tanji, K., Arias-Mendoza, F., Quinzii, C.M. and Hirano, M. (2014) Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. *Brain*, **137**, 1337-1349.
177. Kimura, T., Takeda, S., Sagiya, Y., Gotoh, M., Nakamura, Y. and Arakawa, H. (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. *Nat Genet*, **34**, 440-445.
178. Hance, N., Ekstrand, M.I. and Trifunovic, A. (2005) Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis. *Hum Mol Genet*, **14**, 1775-1783.
179. Lewis, W., Day, B.J., Kohler, J.J., Hosseini, S.H., Chan, S.S., Green, E.C., Haase, C.P., Keebaugh, E.S., Long, R., Ludaway, T. *et al.* (2007) Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. *Laboratory investigation; a journal of technical methods and pathology*, **87**, 326-335.
180. Humble, M.M., Young, M.J., Foley, J.F., Pandiri, A.R., Travlos, G.S. and Copeland, W.C. (2013) Polg2 is essential for mammalian embryogenesis and is required for mtDNA maintenance. *Hum Mol Genet*, **22**, 1017-1025.
181. Zhang, D., Mott, J.L., Chang, S.W., Denniger, G., Feng, Z. and Zassenhaus, H.P. (2000) Construction of transgenic mice with tissue-specific acceleration of mitochondrial DNA mutagenesis. *Genomics*, **69**, 151-161.
182. Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J.N., Rovio, A.T., Bruder, C.E., Bohlooly, Y.M., Gidlof, S., Oldfors, A., Wibom, R. *et al.* (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature*, **429**, 417-423.
183. Kasahara, T., Kubota, M., Miyauchi, T., Noda, Y., Mouri, A., Nabeshima, T. and Kato, T. (2006) Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. *Mol Psychiatry*, **11**, 577-593.
184. Bensch, K.G., Mott, J.L., Chang, S.W., Hansen, P.A., Moxley, M.A., Chambers, K.T., de Graaf, W., Zassenhaus, H.P. and Corbett, J.A. (2009) Selective mtDNA mutation

- accumulation results in beta-cell apoptosis and diabetes development. *American journal of physiology. Endocrinology and metabolism*, **296**, E672-680.
185. Edgar, D., Shabalina, I., Camara, Y., Wredenberg, A., Calvaruso, M.A., Nijtmans, L., Nedergaard, J., Cannon, B., Larsson, N.G. and Trifunovic, A. (2009) Random point mutations with major effects on protein-coding genes are the driving force behind premature aging in mtDNA mutator mice. *Cell metabolism*, **10**, 131-138.
  186. Ahlqvist, K.J., Hamalainen, R.H., Yatsuga, S., Uutela, M., Terzioglu, M., Gotz, A., Forsstrom, S., Salven, P., Angers-Loustau, A., Kopra, O.H. *et al.* (2012) Somatic progenitor cell vulnerability to mitochondrial DNA mutagenesis underlies progeroid phenotypes in Polg mutator mice. *Cell metabolism*, **15**, 100-109.
  187. Donti, T.R., Stromberger, C., Ge, M., Eldin, K.W., Craigen, W.J. and Graham, B.H. (2014) Screen for abnormal mitochondrial phenotypes in mouse embryonic stem cells identifies a model for succinyl-CoA ligase deficiency and mtDNA depletion. *Disease models & mechanisms*, **7**, 271-280.
  188. Milenkovic, D., Matic, S., Kuhl, I., Ruzzenente, B., Freyer, C., Jemt, E., Park, C.B., Falkenberg, M. and Larsson, N.G. (2013) TWINKLE is an essential mitochondrial helicase required for synthesis of nascent D-loop strands and complete mtDNA replication. *Hum Mol Genet*, **22**, 1983-1993.
  189. Tynismaa, H., Mjosund, K.P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink, J.N., Paetau, A. and Suomalainen, A. (2005) Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. *P Natl Acad Sci USA*, **102**, 17687-17692.
  190. Goffart, S., Cooper, H.M., Tynismaa, H., Wanrooij, S., Suomalainen, A. and Spelbrink, J.N. (2009) Twinkle mutations associated with autosomal dominant progressive external ophthalmoplegia lead to impaired helicase function and in vivo mtDNA replication stalling. *Hum Mol Genet*, **18**, 328-340.
  191. Tynismaa, H., Carroll, C.J., Raimundo, N., Ahola-Erkkila, S., Wenz, T., Ruhanen, H., Guse, K., Hemminki, A., Peltola-Mjosund, K.E., Tulkki, V. *et al.* (2010) Mitochondrial myopathy induces a starvation-like response. *Hum Mol Genet*, **19**, 3948-3958.
  192. Viscomi, C., Spinazzola, A., Maggioni, M., Fernandez-Vizarra, E., Massa, V., Pagano, C., Vettor, R., Mora, M. and Zeviani, M. (2009) Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. *Hum Mol Genet*, **18**, 12-26.
  193. Dalla Rosa, I., Camara, Y., Durigon, R., Moss, C.F., Vidoni, S., Akman, G., Hunt, L., Johnson, M.A., Grocott, S., Wang, L. *et al.* (2016) MPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in Mitochondria. *PLoS genetics*, **12**, e1005779.
  194. Warburg, O. (1956) On respiratory impairment in cancer cells. *Science*, **124**, 269-270.
  195. DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G. and Thompson, C.B. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell metabolism*, **7**, 11-20.
  196. Vyas, S., Zaganjor, E. and Haigis, M.C. (2016) Mitochondria and Cancer. *Cell*, **166**, 555-566.
  197. Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A.L., Kafri, R., Kirschner, M.W., Clish, C.B. and Mootha, V.K. (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. *Science*, **336**, 1040-1044.
  198. Hu, J., Locasale, J.W., Bielas, J.H., O'Sullivan, J., Sheahan, K., Cantley, L.C., Vander Heiden, M.G. and Vitkup, D. (2013) Heterogeneity of tumor-induced gene expression changes in the human metabolic network. *Nature biotechnology*, **31**, 522-529.
  199. Sullivan, L.B., Gui, D.Y. and Vander Heiden, M.G. (2016) Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. *Nature reviews. Cancer*.
  200. Gutierrez-Aguilar, M. and Baines, C.P. (2013) Physiological and pathological roles of mitochondrial SLC25 carriers. *The Biochemical journal*, **454**, 371-386.
  201. Palmieri, F. (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. *Molecular aspects of medicine*, **34**, 465-484.
  202. Mizuarai, S., Miki, S., Araki, H., Takahashi, K. and Kotani, H. (2005) Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. *The Journal of biological chemistry*, **280**, 32434-32441.

203. Palmieri, F., Prezioso, G., Quagliariello, E. and Klingenberg, M. (1971) Kinetic study of the dicarboxylate carrier in rat liver mitochondria. *European journal of biochemistry / FEBS*, **22**, 66-74.
204. Johnson, R.N. and Chappell, J.B. (1973) The transport of inorganic phosphate by the mitochondrial dicarboxylate carrier. *The Biochemical journal*, **134**, 769-774.
205. Crompton, M., Palmieri, F., Capano, M. and Quagliariello, E. (1974) The transport of thiosulphate in rat liver mitochondria. *FEBS letters*, **46**, 247-250.
206. Crompton, M., Palmieri, F., Capano, M. and Quagliariello, E. (1974) The transport of sulphate and sulphite in rat liver mitochondria. *The Biochemical journal*, **142**, 127-137.
207. Fiermonte, G., Dolce, V., Arrigoni, R., Runswick, M.J., Walker, J.E. and Palmieri, F. (1999) Organization and sequence of the gene for the human mitochondrial dicarboxylate carrier: evolution of the carrier family. *The Biochemical journal*, **344 Pt 3**, 953-960.
208. Das, K., Lewis, R.Y., Combatsiaris, T.P., Lin, Y., Shapiro, L., Charron, M.J. and Scherer, P.E. (1999) Predominant expression of the mitochondrial dicarboxylate carrier in white adipose tissue. *The Biochemical journal*, **344 Pt 2**, 313-320.
209. Kaplan, R.S., Mayor, J.A. and Wood, D.O. (1993) The mitochondrial tricarboxylate transport protein. cDNA cloning, primary structure, and comparison with other mitochondrial transport proteins. *The Journal of biological chemistry*, **268**, 13682-13690.
210. Huypens, P., Pillai, R., Sheinin, T., Schaefer, S., Huang, M., Odegaard, M.L., Ronnebaum, S.M., Wettig, S.D. and Joseph, J.W. (2011) The dicarboxylate carrier plays a role in mitochondrial malate transport and in the regulation of glucose-stimulated insulin secretion from rat pancreatic beta cells. *Diabetologia*, **54**, 135-145.
211. Lin, Y., Berg, A.H., Iyengar, P., Lam, T.K., Giacca, A., Combs, T.P., Rajala, M.W., Du, X., Rollman, B., Li, W. *et al.* (2005) The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. *The Journal of biological chemistry*, **280**, 4617-4626.
212. Chen, Z. and Lash, L.H. (1998) Evidence for mitochondrial uptake of glutathione by dicarboxylate and 2-oxoglutarate carriers. *The Journal of pharmacology and experimental therapeutics*, **285**, 608-618.
213. Chen, Z., Putt, D.A. and Lash, L.H. (2000) Enrichment and functional reconstitution of glutathione transport activity from rabbit kidney mitochondria: further evidence for the role of the dicarboxylate and 2-oxoglutarate carriers in mitochondrial glutathione transport. *Archives of biochemistry and biophysics*, **373**, 193-202.
214. Wallace, D.C. (1999) Mitochondrial diseases in man and mouse. *Science*, **283**, 1482-1488.
215. Patti, M.E. and Corvera, S. (2010) The role of mitochondria in the pathogenesis of type 2 diabetes. *Endocrine reviews*, **31**, 364-395.
216. Coskun, P., Wyrembak, J., Schriener, S.E., Chen, H.W., Marciniack, C., Laferla, F. and Wallace, D.C. (2012) A mitochondrial etiology of Alzheimer and Parkinson disease. *Biochimica et biophysica acta*, **1820**, 553-564.
217. Kanabus, M., Heales, S.J. and Rahman, S. (2014) Development of pharmacological strategies for mitochondrial disorders. *British journal of pharmacology*, **171**, 1798-1817.
218. Dimmock, D.P., Dunn, J.K., Feigenbaum, A., Rugar, A., Horvath, R., Freisinger, P., Mousson de Camaret, B., Wong, L.J. and Scaglia, F. (2008) Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*, **14**, 1480-1485.
219. Grabhorn, E., Tsiakas, K., Herden, U., Fischer, L., Freisinger, P., Marquardt, T., Ganschow, R., Briem-Richter, A. and Santer, R. (2014) Long-term outcomes after liver transplantation for deoxyguanosine kinase deficiency: a single-center experience and a review of the literature. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*, **20**, 464-472.
220. Freisinger, P., Futterer, N., Lankes, E., Gempel, K., Berger, T.M., Spalinger, J., Hoerbe, A., Schwantes, C., Lindner, M., Santer, R. *et al.* (2006) Hepatocerebral mitochondrial DNA depletion syndrome caused by deoxyguanosine kinase (DGUOK) mutations. *Archives of neurology*, **63**, 1129-1134.

221. Wong, L.J., Brunetti-Pierri, N., Zhang, Q., Yazigi, N., Bove, K.E., Dahms, B.B., Puchowicz, M.A., Gonzalez-Gomez, I., Schmitt, E.S., Truong, C.K. *et al.* (2007) Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy. *Hepatology*, **46**, 1218-1227.
222. Parini, R., Furlan, F., Notarangelo, L., Spinazzola, A., Uziel, G., Strisciuglio, P., Concolino, D., Corbetta, C., Nebbia, G., Menni, F. *et al.* (2009) Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. *Journal of hepatology*, **50**, 215-221.
223. Kaji, S., Murayama, K., Nagata, I., Nagasaka, H., Takayanagi, M., Ohtake, A., Iwasa, H., Nishiyama, M., Okazaki, Y., Harashima, H. *et al.* (2009) Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. *Molecular genetics and metabolism*, **97**, 292-296.
224. Lara, M.C., Weiss, B., Illa, I., Madoz, P., Massuet, L., Andreu, A.L., Valentino, M.L., Anikster, Y., Hirano, M. and Marti, R. (2006) Infusion of platelets transiently reduces nucleoside overload in MNGIE. *Neurology*, **67**, 1461-1463.
225. Hirano, M., Marti, R., Casali, C., Tadesse, S., Uldrick, T., Fine, B., Escolar, D.M., Valentino, M.L., Nishino, I., Hesdorffer, C. *et al.* (2006) Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. *Neurology*, **67**, 1458-1460.
226. Rahman, S. and Hargreaves, I.P. (2007) Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. *Neurology*, **68**, 1872; author reply 1872; discussion 1872-1873.
227. Yavuz, H., Ozel, A., Christensen, M., Christensen, E., Schwartz, M., Elmaci, M. and Vissing, J. (2007) Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. *Archives of neurology*, **64**, 435-438.
228. Taanman, J.W., Muddle, J.R. and Muntau, A.C. (2003) Mitochondrial DNA depletion can be prevented by dGMP and dAMP supplementation in a resting culture of deoxyguanosine kinase-deficient fibroblasts. *Hum Mol Genet*, **12**, 1839-1845.
229. Bulst, S., Abicht, A., Holinski-Feder, E., Muller-Ziermann, S., Koehler, U., Thirion, C., Walter, M.C., Stewart, J.D., Chinnery, P.F., Lochmuller, H. *et al.* (2009) In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. *Hum Mol Genet*, **18**, 1590-1599.
230. Garone, C., Garcia-Diaz, B., Emmanuele, V., Lopez, L.C., Tadesse, S., Akman, H.O., Tanji, K., Quinzii, C.M. and Hirano, M. (2014) Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. *EMBO molecular medicine*, **6**, 1016-1027.
231. Di Meo, I., Auricchio, A., Lamperti, C., Burlina, A., Viscomi, C. and Zeviani, M. (2012) Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. *EMBO molecular medicine*, **4**, 1008-1014.
232. Torres-Torronteras, J., Viscomi, C., Cabrera-Perez, R., Camara, Y., Di Meo, I., Barquinero, J., Auricchio, A., Pizzorno, G., Hirano, M., Zeviani, M. *et al.* (2014) Gene Therapy Using a Liver-targeted AAV Vector Restores Nucleoside and Nucleotide Homeostasis in a Murine Model of MNGIE. *Molecular therapy : the journal of the American Society of Gene Therapy*.
233. Hay, N. (2016) Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? *Nature reviews. Cancer*, **16**, 635-649.
234. Doherty, J.R. and Cleveland, J.L. (2013) Targeting lactate metabolism for cancer therapeutics. *The Journal of clinical investigation*, **123**, 3685-3692.
235. Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.K., Boxer, M.B., Hong, B.S., Tempel, W., Dimov, S., Shen, M., Jha, A. *et al.* (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. *Nature chemical biology*, **8**, 839-847.
236. Gao, P., Tchernyshyov, I., Chang, T.C., Lee, Y.S., Kita, K., Ochi, T., Zeller, K.I., De Marzo, A.M., Van Eyk, J.E., Mendell, J.T. *et al.* (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature*, **458**, 762-765.
237. Gaglio, D., Metallo, C.M., Gameiro, P.A., Hiller, K., Danna, L.S., Balestrieri, C., Alberghina, L., Stephanopoulos, G. and Chiaradonna, F. (2011) Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. *Molecular systems biology*, **7**, 523.
238. Altman, B.J., Stine, Z.E. and Dang, C.V. (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. *Nature reviews. Cancer*, **16**, 619-634.

239. Cairns, R.A., Harris, I.S. and Mak, T.W. (2011) Regulation of cancer cell metabolism. *Nature reviews. Cancer*, **11**, 85-95.
240. Glasauer, A., Sena, L.A., Diebold, L.P., Mazar, A.P. and Chandel, N.S. (2014) Targeting SOD1 reduces experimental non-small-cell lung cancer. *The Journal of clinical investigation*, **124**, 117-128.
241. Raj, L., Ide, T., Gurkar, A.U., Foley, M., Schenone, M., Li, X., Tolliday, N.J., Golub, T.R., Carr, S.A., Shamji, A.F. *et al.* (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. *Nature*, **475**, 231-234.
242. Weinberg, S.E. and Chandel, N.S. (2015) Targeting mitochondria metabolism for cancer therapy. *Nature chemical biology*, **11**, 9-15.
243. Sherman, P.A. and Fyfe, J.A. (1989) Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. *Analytical biochemistry*, **180**, 222-226.
244. Sharma, H., Singh, A., Sharma, C., Jain, S.K. and Singh, N. (2005) Mutations in the mitochondrial DNA D-loop region are frequent in cervical cancer. *Cancer cell international*, **5**, 34.